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ABSTRACT 
 
   miR-191 expression is frequently altered in several neoplasias, being 
upregulated in some, such as pancreatic, colon, lung and prostate carinomas, 
and downregulated in others, such as severe medulloblastomas and melanomas. 
I have investigated  the expression of miR-191 in thyroid neoplasias.  
In my thesis I report that miR-191 is downregulated in follicular adenomas and 
carcinomas, with a reduction that is almost 2-fold higher in follicular 
carcinomas with respect to adenomas. Conversely it is upregulated in thyroid 
carcinomas of the papillary histotype (PTCs), in comparison with the normal 
thyroid tissue. Consistent with a putative tumour suppressor role of miR-191 in 
the development of thyroid neoplasias of the follicular histotype, functional 
studies showed that restoration of miR-191 expression in a follicular thyroid 
cancer cell line reduces cell growth and migration rate. Furthermore, I found 
that miR-191 negatively regulates the expression of CDK6 protein, involved in 
cell cycle control, without changing the CDK6 mRNA level and decreases the 
activity of a luciferase reporter construct containing the CDK6-3'untranslated 
region. These results demonstrate that miR-191 regulates CDK6 at the post-
transcriptional level, resulting in inhibition of cell proliferation and migration 
of the follicular thyroid carcinoma cell line; I will show that restoration of 
miR-191 expression reduces cell proliferation leading to an increased number 
of the cells in the G1 phase of the cell cycle. Finally, in follicular adenomas 
and carcinomas, we immunohistochemically detected CDK6 over-expression, 
suggesting that miR-191 may have a pathogenic role in thyroid cancer by 
controlling CDK6 expression. 
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1. BACKGROUND  
 
   Carcinoma of the thyroid gland is an uncommon cancer, but one of the most 
frequent malignancies of the endocrine system. Most thyroid cancers are 
derived from the follicular cells; follicular carcinoma is considered more 
malignant than papillary thyroid carcinoma (PTC) and anaplastic thyroid 
cancer (ATC) is one of the most lethal human cancers.  
Some years ago, several studies were undertaken to analyze the expression of 
microRNAs (miRNAs or miRs) in thyroid carcinoma to evaluate a possible 
role of their deregulation in the process of carcinogenesis. These studies 
showed an aberrant microRNA expression profile that distinguishes 
unequivocally among tumoral and normal thyroid tissue. 
 
 
1.1 Thyroid gland 
 
   The thyroid gland, which is the largest endocrine organ in humans, regulates 
systemic metabolism through thyroid hormones. It is composed of two distinct 
hormone-producing cell types that have been designated follicular cells and 
parafollicular C cells (reviewed in Kondo T. et al. 2006). Follicular cells 
comprise most of the epithelium and are responsible for iodine uptake and 
thyroid hormones (triidothyronine and thyroxine) synthesis, which play an 
important role in development, differentiation, and metabolism (Zhang and 
Lazar 2000). The synthesis, storage and secretion of thyroid hormones L-
triiodothyronine (T3) and L- thyroxine (T4) is under the control of the 
hypothalamic–pituitary axis with negative feedback by the thyroid hormones 
(Figure 1). Thyrotropin releasing hormone (TRH), which is secreted from the 
hypothalamus, stimulates the release of thyroid-stimulating hormone (TSH) 
from the anterior pituitary gland and TSH stimulates the follicular cells to 
synthesize and secrete thyroid hormones (Martin 1996). 
C cells are scattered intrafollicular or parafollicular cells that are dedicated to 
the production of the calcium-regulating hormone calcitonin (reviewed Kondo 
T. et al. 2006).  
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Figure 1  Schematic representation of thyroid gland structure and function. This butterfly-shaped organ 
that weighs 15– 25 g is located on the anterior surface of the trachea at the base of the neck. It is 
comprised of aggregates or lobules of spherical follicles that are filled with colloid. Thyroid follicular cell 
synthesize, store and secrete thyroid hormones T3 and T4 under the control of the hypothalamic-
piyuitary, which axis with negative feedbach by the thyroid hormones. 
 
 
 
1.1.1 Thyroid cancer 
 
   Cancer of the thyroid is the most common endocrine malignancy and 
incidence rates have steadily increased over recent decades (Kondo T. et al. 
2006). Thyroid nodules can be hyperplastic benign adenomas or malignant 
lesions, and can be derived from thyroid follicular epithelial cells or C cells. 
Cancers that arise in the thyroid are the most common malignancy of endocrine 
organs (Parkin, D. M. et al. 2005). Age-adjusted global incidence rates vary 
from 0.5 to 10 cases per 100,000 population (DeLellis, R. A. et al. 2004). More 
than 95% of thyroid carcinomas are derived from follicular cells (Table 1); a 
minority of tumours (3%), referred to as medullary thyroid carcinoma, are of 
C-cell origin. Most carcinomas that are derived from follicular epithelial cells 
are indolent tumours that can be effectively managed by surgical resection. 
However, a subset of these tumours can behave aggressively and there is 
currently no effective form of treatment. Radiation exposure, reduced iodine 
intake, lymphocytic thyroiditis, hormonal factors and family history are 
putative risk factors for thyroid carcinoma. Iodine is required for thyroid 
hormone organification and a dietary iodine deficiency results in thyroid 
proliferation, known as goitre, as a compensatory mechanism. 
 12 
Tumour type Prevalence 
Sex ratio 
female:male 
Age 
(years) 
Lymph-node 
metastasis 
Distant 
metastasis 
Survival 
rate 
(5 year) 
References 
Papillary thyroid 
carcinoma 
85–90% 2:1–4: 1 20–50 <50% 5–7% >90% 
Hundahl et al. 1998, 
DeLellis et al. 2004, 
LiVolsi et al. 1994. 
Follicular thyroid 
carcinoma 
<10% 2:1–3: 1 40–60 <5% 20% >90% 
Hundahl et al. 1998, 
DeLellis et al. 2004, 
LiVolsi et al. 1994. 
Poorly 
differentiated 
thyroid 
carcinoma 
rare–7% 0,4:1–2,1: 1 50–60 30–80% 30–80% 50% 
Hundahl et al. 1998, 
DeLellis et al. 2004, 
Carcangiu et al. 1984, 
Rodriguez et al. 1998. 
Undifferentiated 
thyroid 
carcinoma 
2% 1,5: 1 60–80 40% 20–50% 1–17% 
Hundahl et al. 1998, 
DeLellis et al. 2004, 
Kebebew et al. 2005. 
Medullary 
thyroid 
carcinoma 
3% 1:1–1,2: 1 30–60 50% 15% 80% 
Hundahl et al. 1998, 
DeLellis et al. 2004. 
Mixed medullary 
and follicular-cell 
carcinoma 
rare      DeLellis et al. 2004,  
 
Table 1 Clinico-pathological features of thyroid cancer (copyroght © 2006 Nature Publishing Group). 
 
 
 
 
 
 
 
 
Follicular-cell-derived carcinomas are broadly divided into well-differentiated 
thyroid carcinoma (WDTC), poorly differentiated thyroid carcinoma (PDTC) 
and undifferentiated types on the  basis of histological and clinical parameters 
(Table 1). WDTCs include papillary thyroid carcinoma (PTC) and follicular 
thyroid carcinoma (FTC) types. Although initially defined by architectural 
criteria, the histological diagnosis of papillary carcinoma rests on a number of 
nuclear features that predict the propensity for metastasis to local lymph nodes 
(DeLellis et al. 2004). The diagnosis of this most frequent type of thyroid 
malignancy (85–90% of thyroid malignancies) has been increasing, possibly 
owing to the changing recognition of nuclear morphological criteria (ground-
glass nuclei). Radiation exposure as a consequence of nuclear fallout is 
associated with papillary carcinoma, as evidenced by the sequelae of the 
atomic bombs of Hiroshima and Nagasaki (1945), nuclear testing in the 
Marshall Islands (1954) and Nevada (1951–1962), and the more recent nuclear 
accident in Chernobyl (1986) (DeLellis et al. 2004, Kazakov et al. 1992). 
On the other hand, follicular thyroid carcinoma is characterized by 
haematogenous spread, and the frequency of its diagnosis has been decreasing 
(LiVolsi and Asa 1994). FTC is well differentiated, usually unifocal, 
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encapsulated, with a tendency to metastasize via the vascular system to the 
bones and lungs. It is likely that FTCs can develop from pre-existing benign 
follicular adenomas (FTAs) or by directly bypassing the stage of adenoma. The 
differential diagnosis between the FTCs and the far more frequent FTAs is 
difficult. The incidence of follicular carcinoma in areas of iodine deficiency is 
higher than in areas of an iodine-rich diet (DeLellis et al. 2004, Harach et al. 
2002). Interestingly, in animal models, iodine supplementation causes 
experimental thyroid cancers to change from follicular to papillary 
morphology, indicating that one of the roles of iodine in thyroid carcinogenesis 
is modulating tumour morphology, rather than cancer initiation (Gasbarri et al. 
2004). 
Most WDTCs behave in an indolent manner and have an excellent prognosis; 
they manifest in patients who are 20–50 years of age, and the disease is 2–4 
times more frequent in females than in males (Hundahl et al. 1998, DeLellis et 
al. 2004). By contrast, undifferentiated or anaplastic thyroid carcinoma (UTC 
or ATC) is a highly aggressive and lethal tumour (DeLellis et al. 2004, 
Kebebew et al. 2005) and insensitive to conventional radiotherapy and 
chemotherapy. The presentation is dramatic, with a rapidly enlarging neck 
mass that invades adjacent tissues. There is currently no effective treatment 
and death usually occurs within 1 year of diagnosis. PDTCs are 
morphologically and behaviourally intermediate between well-differentiated 
and undifferentiated thyroid carcinomas (Table 1) (DeLellis et al. 2004; 
Carcangiu et al. 1984; Rodriguez et al. 1998). 
Two models of thyroid cancerogenesis have been proposed: 1) The theory of 
sequential progression of well-differentiated thyroid carcinoma through the 
spectrum of poorly differentiated to undifferentiated thyroid carcinoma (Figure 
2), supported by the presence of pre- or co-existing well-differentiated thyroid 
carcinoma with less differentiated types, and the common core of genetic loci 
with identical allelic imbalances in co-existing well differentiated components 
(Van der Laan et al. 1993; Hunt et al. 2003); 2) The thyroid cancer stem cell 
origin that holds thyroid cancer stem cells originate either from normal stem 
cells, progenitor cells, or more mature cells that have dedifferentiated. 
Although any of these origins is possible, most researchers believe that stem 
cells or progenitor cells are the most likely culprits. Zhang et al. (2006) 
presented a model for the origin of the four types of thyroid carcinomas based 
on their differentiation levels. Anaplastic cancer could form directly from a 
stem cell because it is poorly differentiated. Follicular and papillary 
carcinomas, which are well-differentiated, could arise from bipotential stem 
cells. Meduallary carcinoma, another well-differentiated cancer, could 
originate from progenitor C cells (Zhang et al. 2006). Although the discovery 
of stem cell markers in the thyroid gland indicates the potential for the 
existence of thyroid cancer stem cells, the identification of these cells could 
prove to be quite difficult due to the extremely low lifetime turnover in the 
thyroid gland. 
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Figure 2 Model of multi-step carcinogenesis of thyroid neoplasms. The proposed model of thyroid 
carcinogenesis is based on general concepts and specific pathways. On the basis of clinical, histological 
and molecular observations, three distinct pathways are proposed for neoplastic proliferation of thyroid 
follicular cells, including hyper-functioning follicular thyroid adenoma (tumours that are almost always 
benign lesions without a propensity for progression), follicular thyroid carcinoma and papillary thyroid 
carcinoma. Genetic defects that result in activation of RET or BRAF represent early, frequent initiating 
events that can be associated with radiation exposure. Underexpression of the cyclin-dependent-kinase 
inhibitor p27KIP1 and overexpression of cyclin D1 are strong predictors of lymph-node metastases in 
papillary thyroid carcinomas. Most poorly differentiated and undifferentiated thyroid carcinomas are 
considered to derive from pre-existing well-differentiated thyroid carcinoma through additional genetic 
events, including β-catenin (which is encoded by CTNNB1) nuclear accumulation and p53 inactivation, 
but de novo occurrence might also occur. GNAS1, guanine nucleotide-binding α-subunit 1; PPARg, 
peroxisome proliferation-activated receptor-γ; TSHR, thyroid-stimulating-hormone receptor (reviewed on 
Kondo et al. 2006). 
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Genomic alternations, such as RET/PTC and PAX8-PPARg1 rearrangements 
and a mutation in the BRAF gene, play an oncogenic role by preventing 
thyroid fetal cells from differentiating (Figure 3). This hypothesis well explains 
the clinical and biological features and recent molecular evidence of thyroid 
cancer. Further, it underscores the importance of identifying stem cells and 
clarifying the molecular mechanism of organ development. Such data will lead 
to better understanding of thyroid carcinogenesis and the establishment of 
more accurate diagnostic methods and more effective therapies (Takano 2007).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Schematic representation showing a developmental hierarchy of fetal thyroid stem/progenitor 
cells as a potential cause of specific follicular thyroid cancer types (Klonisch 2009, Takano 2007). 
Examples of mutations associated with and factors expressed in certain thyroid cancer types are depicted. 
Trefoil factor 3 (TFF3) may be used to distinguish foci of thyroid TTF3+ adenoma from TTF3weak/- FTC. 
FTC, follicular thyroid carcinoma; PTC, papillary thyroid carcinoma; UTC, undifferentiated anaplastic 
thyroid carcinoma. 
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1.1.2 Genetic alterations in signalling pathways 
 
   Genetic factors other than the environmental ones may as well play a role in 
thyroid carcinogenesis. There is also a genetic component to thyroid follicular 
cell-derived carcinoma, as a family history increases risk 3.2- and 6.2-fold 
when a parent and a sibling, respectively, have had thyroid cancer (Hemminki 
et al. 2005). Familial thyroid cancers associated with tumour syndromes caused 
by known germline mutations include familial polyposis coli (associated with 
mutations in the adenomatosis polyposis coli gene (APC)), Cowden disease 
(associated with mutations in the phosphatase with tensin homology gene 
(PTEN)) and Werner syndrome (associated with mutations in the WRN Gene) 
(Lindor and Greene 1998). It has recently been shown that an important role to 
the onset of familial PTCs and FTCs can be attributed to the common variants 
of thyroid transcription factor 2 (TTF2) or factor 1 (TTF1) genes; these 
variants account for an increased risk of both PTCs and FTCs (Gudmundsson 
et al. 2009). 
Several oncogenes have been involved in thyroid carcinoma development 
(Table 2). In PTCs, nonoverlapping mutations of genes involved in the 
activation pathway of mitogen-activated protein kinase (MAPK), such as RET, 
TRK, RAS, and BRAF, have been found in about 70% of the cases (Kimura et 
al. 2003; Soares et al. 2003; Frattini et al. 2004), while a fraction of about 30% 
of PTCs presents rearrangement of RET proto-oncogene (Santoro et al. 2004). 
The RET/PTC rearrangements consist in the fusion of tyrosine kinase (TK) 
domain of RET with other genes that provide to the chimeric gene the 
promoter and the 5’ coding region. RET/PTC1 and RET/PTC3 are the most 
frequent isoforms found in PTCs.  
In most PTC cases, a specific point mutation of BRAF is found (T1799A, 
resulting in a valine>glutamate substitution at residue 600 (V600E). The proto-
oncogene form of BRAF encodes a serine/threonine kinase that transduces 
regulatory signals through the Ras–Raf–MEK–ERK cascade. Gain-of-function 
BRAF mutation provides an alternative route for the aberrant activation of ERK 
signalling that is implicated in the tumorigenesis of several human cancers — 
for example, melanoma and colon carcinoma (Davies et al. 2002). In PTCs, 
BRAF mutation and RET/PTC rearrangements are mutually exclusive and 
cannot be found simultaneously in the same patients, yet they are not 
completely equivalent, since it has been shown that PTCs positive for BRAF 
are more aggressive than those positive for RET/PTC (Kimura et al. 2003; 
Soares et al. 2003). It has recently been demonstrated that some types of PTCs 
developed after the Chernobyl nuclear accident present a different BRAF 
alteration since they harbored a rearrangement similar to the RET/PTC 
rearrangements, which results in the fusion between BRAF kinase domain and 
the AKAP9 gene and is caused by a paracentric inversion of the long arm of 
chromosome 7 (Ciampi et al. 2005).  
RAS gene mutations represent early molecular lesions since they are also 
frequently found in FTAs which are considered FTC precursors. Three Ras 
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proto-oncogenes — HRAS, KRAS, and NRAS — are implicated in human 
tumorigenesis (Downward 2003). Ras mutations are more common in iodine-
deficient than iodine-sufficient areas and in lesions with follicular architecture 
(including follicular carcinoma and follicular variant papillary thyroid 
carcinoma) than in typical papillary thyroid carcinoma (Shi et al. 1991, Zhu et 
al. 2003) and highly specific analysis indicates that Ras mutations are more 
common in poorly differentiated and undifferentiated thyroid carcinoma, 
implicating this phenomenon in tumour progression (Ezzat et al. 1996, Garcia-
Rostan et al. 2003). Another FTC group presents the fusion of two nuclear 
proteins with transcriptional activity: PAX8 and peroxisome proliferator-
activated receptor g (PPARg; Kroll et al. 2000; Table 2).  
PDTCs and ATCs can originate from WDTCs and, in particular, from PTCs, 
therefore, mutations that occur in the early stages of WDTCs are also observed 
in PDTCs and ATCs.  
Alterations of PIK3CA and PTEN (effectors of phosphoinositide 3-kinase) 
have also been found in thyroid carcinomas. These alterations are generally 
observed in the later stages of thyroid carcinogenesis and are more frequent in 
ATCs than in WDTCs or FTCs (Paes & Ringel 2008; Table 2). This is in 
contrast with mutations of the MAPK effectors that are preferentially 
associated with the early stages of thyroid carcinogenesis.  
More recently, an AKT1 oncogene mutation in PDTCs has also been observed 
(Ricarte-Filho et al. 2009) and this mutation  result commonly associated with 
BRAF mutations (Ricarte-Filho et al. 2009).  
Impairment of the p53 tumor suppressor gene function represents a usual 
feature of ATCs with p53 mutations being common both in PDTCs and in 
ATCs, but rare or absent in WDTCs (Ito et al. 1992, Donghi et al. 1993, Fagin 
et al. 1993; Table 2). 
Moreover, mutations of CTNNB1 (b-catenin) have been found in PDTCs and 
ATCs (Garcia-Rostan et al. 2001, Miyake et al. 2001;Table 2). 
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Tumor histotype Cell type 
Etiological 
factors 
Molecular lesion 
Prevalence 
(%) 
References 
Papillary thyroid 
carcinoma 
Follicular 
cell 
Ionizing 
radiation 
RET 
rearrangement 30 Santoro et al. (2004) 
   
NTRK1 
rearrangement 10 Pierotti et al. (1995) 
   
BRAF mutation 
(V600E) 40 
Kimura et al. (2003) and 
Soares et al. (2003) 
   
RAS mutation 
(codons 12, 13, 
and 61) 10–20 
Namba et al. (1990), Ezzat 
et al. (1996) and Vasko et 
al. (2004) 
Follicular 
thyroid 
Adenoma 
Follicular 
cell 
Iodine 
deficiency 
RAS mutation 
(codons 12, 13, 
and 61) 20–40 
Suarez et al. (1990), Esapa 
et al. (1999), Basolo et al. 
(2000) and Motoi et al. 
(2000) 
   
PAX8/PPARg 
rearrangement 2–10 
Dwight et al. (2003), French 
et al. (2003) and Nikiforova 
et al. (2003) 
Follicular 
thyroid 
carcinoma 
Follicular 
cell 
Iodine 
deficiency 
RAS mutation 
(codons 12, 13, 
and 61) 40–50 
Suarez et al. (1990), Esapa 
et al. (1999), Basolo et al. 
(2000) and Motoi et al. 
(2000) 
   
PAX8/PPARg 
rearrangement 35 
Dwight et al. (2003), French 
et al. (2003) and Nikiforova 
et al. (2003) 
   PIK3CA mutation 8 Paes & Ringel (2008) 
   PTEN mutation 7 Paes & Ringel (2008) 
Poorly 
differentiated 
thyroid 
carcinoma 
Follicular 
cell 
Tumor 
progression 
RET 
rearrangement 13 Santoro et al. (2002) 
   
BRAF mutation 
(V600E) 12–17 
Garcia-Rostan et al. (2005), 
Hou et al. (2007) and 
Santarpia et al. (2008) 
   
RAS mutation 
(codons 12, 13, 
and 61) 46–55  
   TP53 mutation 17–38 
Ito et al. (1992), Donghi et 
al. (1993) and Fagin et al. 
(1993) 
   
CTNNB1 
mutation 25 
Garcia-Rostan et al. (2001) 
and Miyake et al. (2001) 
Anaplastic 
thyroid 
carcinoma 
Follicular 
cell 
Tumor 
progression 
BRAF mutation 
(V600E) 25–29 
Garcia-Rostan et al. (2005), 
Hou et al. (2007) and 
Santarpia et al. (2008) 
   
RAS mutation 
(codons 12, 13, 
and 61) 6–52  
   TP53 mutation 67–88 
Ito et al. (1992), Donghi et 
al. (1993) and Fagin et al. 
(1993) 
   
CTNNB1 
mutation 66 
Garcia-Rostan et al. (2001) 
and Miyake et al. (2001) 
   PIK3CA mutation 16 Paes & Ringel (2008) 
   PTEN mutation 14 Paes & Ringel (2008) 
Table 2 Genetic alterations of human thyroid carcinomas of follicular cell origin. 
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1.1.3 Cell-cycle regulation in thyroid 
 
   The growth activity of well-differentiated thyroid carcinoma is low compared 
with poorly differentiated and undifferentiated thyroid carcinomas and altered 
cell-cycle regulators govern these differences in growth activity. Progression 
factors (for example, cyclin D1, cyclin E1, cyclin-dependent kinases (CDKs) 
and E2Fs) and competitor factors (for example, retinoblastoma protein (RB), 
p16INK4A, p21CIP1, p27KIP1 and p53) regulate the transition from G1 to S 
phase (Figure 4). The cyclin-dependent kinases (Cdks)
1
 are a family of 
serine/threonine protein kinases (~34–40 kDa) that require the binding of a 
regulatory cyclin subunit for activity (in most cases, full activation also 
requires phosphorylation of a threonine residue near the kinase active site). 
Cyclin–CDK complexes promote cell-cycle progression through inactivation of 
RB. Although nuclear immunoreactivity for cyclin D1  and cyclin E1 are not 
detectable in normal thyroid follicular cells, expression of cyclin D1 and cyclin 
E1 is observed in approximately 30% and 76% of papillary thyroid 
carcinomas, respectively (Basolo F. et al. 2000; Brzezinski J. et al. 2004). 
Furthermore, cyclin D1 overexpression correlates with metastatic spread in 
papillary thyroid carcinomas, and significant overexpression of cyclin D1 is 
observed in undifferentiated thyroid carcinoma (Khoo, Beasley et al. 2002, 
Khoo, Ezzat et al. 2002, Wang et al. 2000).  CDK inhibitors are commonly 
downregulated in thyroid neoplasia. There is progressive loss of p21CIP1 with 
advancing tumour stage of papillary thyroid carcinomas (Brzezinski et al. 
2005). Normal and hyperplastic follicular cells show strong immunoreactivity 
for p27KIP1, whereas p27KIP1 expression is significantly reduced in papillary 
thyroid carcinoma, mainly metastatic forms and undifferentiated thyroid 
carcinoma (reviewed in Kondo et al. 2006). The E2F transcription-factor 
family — the main targets of RB —  consists of six members: E2F1–E2F6. 
E2F1, but not other members of this family, is upregulated in WDTCs, PDTCs 
and ATCs (Volante et al. 2002, Onda et al. 2004). 
The tumour-suppressor p53 seems to be a crucial gatekeeper of progression 
from indolent to lethal thyroid cancers; activation of wild-type p53 can lead to 
G1 cell-cycle arrest through p21CIP1, and apoptotic cell death, preventing 
replication of cells with damaged DNA, while loss of- function mutation of 
p53 induces genomic instability, owing to weakened DNA repair systems, and 
subsequent cancer progression (Hosal et al. 1997). 
                                                     
1
 Cyclin-dependent kinases (CDK) belong to a group of protein kinases originally discovered as being 
involved in the regulation of the cell cycle, but they are also involved in the regulation of transcription 
and mRNA processing. 
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Figure  4 Cell-cycle regulation in follicular cells. Cyclin D1 and cyclin E1 cooperate to control the G1 
to S phase transition through interactions with retinoblastoma protein (RB). Cyclin D1 and cyclin E1 
heterodimerize with cyclin-dependent kinases (CDKs) 4 or 6 and 2, respectively, to inactivate the tumour 
suppressor RB by phosphorylation. Active RB functions as a repressor of E2F transcription factors, 
whereas inactivation (phosphorylation) of RB allows E2F transcriptional activity. E2F activates the 
transcription of genes that are involved in the G1 to S phase transition, such as DNA polymerase and 
thymidine kinase. The CDK inhibitors p16INK4A, p21CIP1 and p27KIP1 impair the activity of cyclin–
CDK complexes, thereby preventing phosphorylation of RB. The CDK inhibitors therefore function as 
tumour suppressors. The tumour suppressor p53 induces cell-cycle arrest by upregulating p21CIP1, 
which initiates apoptosis. The function of p53 is controlled by negative regulators, including MDM2. The 
MDM2 protein targets p53 for ubiquitinmediated degradation, constituting a feedback loop to maintain a 
low concentration of p53 in the cells (reviewed in Kondo et al.2006). 
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1.2 MicroRNA 
 
   MicroRNAs (miRNAs or miRs) are a class of endogenous noncoding small 
RNA molecules of 19–25 nucleotides (nt), that negatively regulates gene 
expression by degradation of mRNA or suppression of mRNA translation 
(Bartel 2004). MiRNA plays important roles in physiological processes such as 
cellular development, differentiation, proliferation, apoptosis, and stem cell 
self-renewal. The first glimpse into the new world of small RNAs came with 
seminal papers from Ambros, Ruvkun and colleagues (Lee et al. 1993, 
Wightman et al. 1993): they reported that lin-4 and let-7, the first microRNA 
(miRNA) genes identified, control developmental timing in nematodes by 
modulating the expression of other genes at the post-transcriptional level. We 
now know that miRNAs are a universal and pervasive feature of animal and 
plant genomes and are conserved among distantly related organism. The most 
recent release of the miRBase sequence (http://www.mirbase.org/, 14.0 
released on September 2009) lists 10,886 different miRNAs identified in all 
species, among them are 721 human miRNAs. It is predicted that the human 
genome encodes about 1,000 miRNAs (Bentwich et al. 2005) and that they 
could regulate ~30% of human genes (Berezikov et al. 2005). Deregulation of 
miRNA contributes to a variety of human diseases, such as diabetes, immuno- 
or neurodegenerative disorders, and cancer (Bartel 2004, Pasquinelli et al. 
2005, Harfe 2005, Carleton et al. 2007, Garzon et al. 2006, Wang 2007, Boehm 
and Slack 2006, Poy et al. 2004, Lu et al. 2005). Half of the known miRNAs 
are located inside or close to fragile sites and in minimal regions of loss of 
heterozygosity, minimal regions of amplifications, and common breakpoints 
associated with cancer (Calin et al. 2004). For example, the miRNA cluster 17-
92 is located at 13q31, a region commonly amplified in lymphomas (Ota et al. 
2004); miR-143 and miR-145 are located at 5q33, which is frequently deleted 
in myelodysplastic syndromes (Calin et al. 2004); and a rearrangement of miR-
125b-1, juxtaposed to the immunoglobulin heavy chain locus, was described in 
a patient with B cell acute lymphocytic leukemia (Sonoki et al. 2005). 
MiRNAs may function as oncogenes (OncomiRs) or tumor suppressors 
(TSmiRs) in tumors; mounting evidence shows that miRNAs are aberrantly 
expressed during cancer development (O’Donnell 2005), invasion and 
metastasis (Zhu et al. 2008), angiogenesis (Hua  et al. 2006) and play crucial 
roles in cancer stem cell regulation (Yu et al. 2007).  
Several groups, including ours, have systematically analyzed miRNA 
expression in cancer samples and their corresponding normal tissues (Visone  
et al. 2007, Pallante  et al. 2006). Consequently, miRNA “signatures” were 
discovered that distinguish between tumoral and normal cells, and in some 
instances are associated with the prognosis and the progression of cancer 
(Calin et al. 2005).  
Therefore, miRNAs are integral elements in the post-transcriptional control of 
gene expression and the challenge is now to understand their specific 
biological function and, hopefully exploit them in cancer diagnosis and 
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therapy.  
I will briefly describe miRNA biogenesis and discuss how miRNAs can act as 
oncogenes and tumor suppressors. I will also address the issue of miRNA 
deregulation in the diagnosis, prognosis, and treatment of cancer. 
 
 
1.2.1 miRNA biogenesis 
 
   miRNA genes are evolutionarily conserved and may be located either within 
the introns or exons of protein-coding genes (70%) or in intergenic areas (30%) 
(Rodriguez et al. 2004). Most of the intronic or exonic miRNAs are oriented in 
sense with their host gene, suggesting that they are transcribed in parallel with 
their host transcript. The second group of miRNAs is transcribed from 
intergenic regions or gene deserts comprising independent transcription units 
(Rodriguez et al. 2004). MiRNAs are preferentially transcribed by polymerase 
II (Pol II) into long primary transcripts, up to several kilobases (pri-miRNA) 
that are subsequently processed in the nucleus by the enzyme Drosha to 
become 70-nt-long precursor strands (pre-miRNA) (Figure 5) (Lee Y et al. 
2004, Lee Y et al. 2003). This precursor is exported by exportin 5 to the 
cytoplasm (Bohnsack et al. 2004), where it is bound to the RNase Dicer and to 
the RNA-induced silencing complex (RISC). RISC is composed of the 
transactivation-responsive RNA-binding protein (TRBP) and Argonaute 2 
(Ago2) (Hammond et al. 2000, Thimmaiah et al. 2005). Recent studies suggest 
that first Ago2 cleaves the pre-miRNA 12 nt from its 3’ end (forming Ago2-
cleaved precursor miRNA) and then the Dicer cleaves the Ago2-cleaved 
precursor miRNA into a mature 22-nt miRNA duplex (Diederichs and Haber 
2007). While the active or mature strand is retained in RISC, the passenger 
strand is removed and degraded. miRNAs modulate gene expression through 
canonical base pairing between the seed sequence of the mature miRNA 
(nucleotides 2–8 at its 5′ end) and its complementary seed match sequence 
which is present in the 3’ untranslated region (3′ UTR) of target mRNAs 
(Bartel 2009); in this way mRNA guides the miRNA-RISC complex to repress 
gene expression by inhibiting translation of target (Figure 5) (Bartel 2004, 
Hammond et al. 2000, Thimmaiah et al. 2005, Diederichs and Haber 2007). 
The RISC can inhibit the expression of the target mRNA through two main 
mechanisms that have several variations: removal of the polyA tail 
(deadenylation) by fostering the activity of deadenylases (such as CCR4–
NOT), followed by mRNA degradation; and blockade of translation at the 
initiation step or at the elongation step. For example, by inhibiting eukaryotic 
initiation factor 4E (EIF4E) or causing ribosome stalling, RISC-bound mRNA 
can be localized to sub-cytoplasmatic compartments, known as P-bodies, 
where they are reversibly stored or degraded (Masafumi et al. 2010). 
During miRNA biogenesis, miRNAs are subject to intense transcriptional and 
post-transcriptional regulation and the elucidations of these mechanisms and of 
alterations at the expense of these mechanism has improved our understanding 
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of miRNA deregulation in disease. A cluster of papers in Nature and 
Molecular Cell revealed that a family of miRNAs, miR-34a, -b, and -c, are 
induced directly by TP53 and suggested that some of TP53’s effects could be 
mediated through transcriptional activation of miRNAs. Using different 
models, the authors compared miRNA expression in cells with high or low 
TP53 expression and found that miR-34 expression is increased in cells with 
high TP53 levels. Chromatin immunoprecipitation experiments revealed that 
TP53 binds to the miR-34s promoters. Restoring miR-34 levels in both primary 
and tumor cell lines induced cell cycle arrest by targeting a gene program 
involved in cell cycle progression (He et al. 2007, Raver-Shapira et al. 2007, 
Chang et al. 2007). Our group has shown that HMGA protein activates miR-
181 expression by binding to the microRNA promoter region (Mansueto et al. 
2010). 
An important epigenetic mechanism of miRNA regulation is miRNA 
expression silencing by promoter DNA hypermethylation. Saito et al. first 
reported that miR-127 is silenced by promoter hypermethylation in bladder 
cancer cell lines and patients, and its expression could be restored by using 
hypomethylating agents (Saito Y et al. 2006).  
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Figure 5 The biogenesis of 
microRNAs. MicroRNAs 
(miRNAs) are transcribed by RNA 
polymerase II (Pol II) as primary 
transcripts (pri-miRNAs) in the 
nucleus, which are capped 
(7MGpppG) and polyadenylated 
(AAAAA). Each pri-miRNA 
contains one or more hairpin 
structures that are recognized and 
processed by the microprocessor 
complex, which consists of the 
RNase III type endonuclease 
Drosha and its partner, DGCR8 
(also known as PASHA) (see the 
figure). The microprocessor 
complex generates a 70-nucleotide 
stem loop known as the precursor 
miRNA (pre-miRNA), which is 
actively exported to the cytoplasm 
by exportin 5. In the cytoplasm, 
the pre-miRNA is recognized by 
Dicer, another RNase III type 
endonuclease, and TAR RNA-
binding protein (TRBP; also 
known as TARBP2). Dicer cleaves 
this precursor, generating a 20-
nucleotide mature miRNA duplex. 
Generally, only one strand is 
selected as the biologically active 
mature miRNA and the other 
strand is degraded. miRNA duplex 
is loaded into the miRNA-
associated multiprotein RNA-
induced silencing complex 
(miRISC), which includes the 
Argonaute (Ago) proteins, and the 
mature single-stranded miRNA is 
preferentially retained in this 
complex. The mature miRNA 
allows the RISC to recognize 
target mRNAs to negatively 
regulate gene expression in one of 
two ways that depend on the 
degree of complementarity 
between the miRNA and its target. 
miRNAs that bind to mRNA 
targets with imperfect 
complementarity block target gene 
expression at the level of protein 
translation. However, recent evidence indicates that miRNAs that bind to mRNA targets with imperfect 
complementarity might also affect on mRNA stability. In particular, perfect base pairing between the 
seed sequence of the miRNA (from the second to the eighth nucleotide) and the seed match sequences in 
the mRNA 3′ UTR are crucial. The RISC can inhibit the expression of the target mRNA through two 
main mechanisms that have several variations: removal of the polyA tail (deadenylation) by fostering the 
activity of deadenylases (such as CCR4–NOT), followed by mRNA degradation; and blockade of 
translation at the initiation step or at the elongation step; for example, by inhibiting eukaryotic initiation 
factor 4E (EIF4E) or causing ribosome stalling RISC-bound mRNA can be localized to sub-cytoplasmatic 
compartments, known as P-bodies, where they are reversibly stored or degraded (Masafumi et al. 2010). 
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1.2.2 miRNAs as tumor suppressors (TSmiRs) 
 
   Like a protein-coding gene, a miRNA can act as a tumor suppressor 
(TSmiRs) when its function loss can initiate or contribute to the malignant 
transformation of a normal cell. The loss of function of a miRNA could be due 
to several mechanisms, including genomic deletion, mutation, epigenetic 
silencing, and/or miRNA processing alterations (Calin et al. 2002, Calin et al. 
2005, Saito et al. 2006, Nakamura 2007). For example, the miR-15b and miR-
16 clusters at 13q14 were identified as the first TSmiRs because they are 
deleted and/or downregulated in about 68% of B-cell chronic lymphocytic 
leukemia (CLL) samples (Bullrich et al. 2001, Doehner et al. 2000). MiR-15b 
and miR-16 have been shown to control the expression of VEGF, a key 
proangiogenic factor involving in tumor angiogenesis (Hua et al. 2006). In 
addition, miR-15b and miR-16 also induce apoptosis of leukemic cells by 
affecting the antiapoptotic protein Bcl-2 (Calin et al. 2005, Cimmino et al. 
2006) (Tabella 3). Furthermore, ectopic expression of miR-16  negatively 
regulates cell growth and cell cycle progression and induces apoptosis in 
several human cancer cell lines and in a leukemic xenograft model (Linsley et 
al. 2007, Calin et al. 2008).  
Reduced expression of another group of tumor suppressive miRNAs, the let-7 
family members, is a common genetic event in non-small cell lung cancer and 
is associated with a poor prognosis. The let-7 family is able to negatively 
regulate let-60/RAS, providing a possible mechanism for let-7 deficiency in 
cancers (Johnson et al. 2005, Akao et al. 2006). In addition, let-7 regulates late 
embryonic development by suppressing the expression of a number of genes, 
such as c-Myc and RAS, and the embryonic gene, high-mobility group A2 
(HMGA2) (Lee and Dutta  2007). Let-7 family induces cancer stem cell 
differentiation in breast cancer (Yu et al. 2007).  
MiRNAs not only are regulated by DNA methylation but also modulate DNA 
methylation in cancer by interfering with the DNA methylation machinery 
(Garzon R et al. 2008). For example, it has been reported that the miR-29 
family, which includes targets DNMT3A and -3B, induces global DNA 
hypomethylation and tumor suppressor gene re-expression in lung cancer 
(Garzon R et al. 2008). Interestingly, miR-29s are downregulated in lung 
cancer patients, and an inverse correlation was found between miR-29b and 
DNMT3B expression, suggesting that the downregulation of this miRNA may 
contribute to increased DNMT3 levels, as well as hypermethylation and 
silencing of tumor suppressor genes in lung cancer (Yanaihara et al. 2006, 
Fabbri M et al. 2007). 
Taken together, reduction of TSmiRs expression in cancers activates the 
oncogenic genes and promotes the tumor initiation and progression. Many 
other miRNAs are believed to act as tumor suppressors, although the evidence 
supporting those claims is merely correlative. Substantial experimental data are 
lacking, and miRNA knockout mice that develop or are predisposed to cancer 
have not been yet reported. It is noteworthy that most of the miRNAs with a 
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clear tumor suppressor role (e.g., miR-15b and 16, miR-29s, and let-7) have 
more than one genomic location, and although they are transcribed from 
different precursors, the mature miRNA is identical. The presence of more than 
one genomic copy of the miRNA could be an evolutionarily conserved 
mechanism to preserve function of an important miRNA if one allele is deleted 
or silenced. 
 
 
1.2.3 miRNAs as oncogenes (Oncomir) 
 
   The list of miRNAs that function as oncogenes is short, but the evidence for 
their role in cancer is very strong (Tabella 3). MiR-155 was one of the first 
described (Metzler et al. 2004, Kluiver et al. 2005). It is embedded in a host 
noncoding RNA named the B cell integration cluster (BIC) and is located in 
chromosome 21q23. A previous study showed the ability of BIC to cooperate 
with c-myc in oncogenesis. The coexpression of c-myc and BIC, either singly 
or pairwise, in cultured chicken embryo fibroblasts using replication-competent 
retrovirus vectors caused growth enhancement of cells (Tam et al. 2002). 
Several groups have shown that miR-155 is highly expressed in pediatric 
Burkitt lymphoma (Metzler et al. 2004.), Hodgkin disease (Kluiver et al. 
2005), CLL (Calin et al. 2005), AML (Garzon et al. 2008), lung cancer 
(Yanaihara et al. 2006), and breast cancer (Iorio et al. 2005). Little is known, 
however, about the regulation of miR-155/BIC and the mechanism of its 
overexpression in cancer. A role for this miRNA in early leukemogenesis was 
proven in a transgenic mouse model with a B cell–targeted overexpression of 
miR-155, which underwent a polyclonal preleukemic pre–B cell proliferation 
followed by full-blown B cell malignancy (Tabella 3) (Costinean et al. 2006). 
The miR-17-92 cluster, which comprises six miRNAs (miR-17, miR-18a, miR-
19a, miR-20a, miR-19b-1, and miR-92-1), is located within 800 base pairs in 
the noncoding gene C13orf25 at 13q31.3. This region is frequently amplified in 
follicular lymphoma and diffuse large B cell lymphoma (Ota A et al. 2004). 
Members of the miR-17-92 cluster are highly expressed in a variety of solid 
tumors and hematological malignancies, including cancers of the breast, colon, 
lung, pancreas, prostate, and stomach as well as lymphomas (Tabella 3) 
(Mendell 2008). These miRNAs promote proliferation, inhibit apoptosis, 
induce tumor angiogenesis, and cooperate with c-myc to cause lymphoma in 
mice (Mendell 2008). Interestingly, the miR-17-92 cluster is transactivated by 
c-myc, an oncogene that is frequently activated in cancer (O’Donnell KA et al. 
2005). The effects of this cluster’s expression on cell cycle and proliferation 
are partly due to its regulation of E2F transcription factors, which are critical 
regulators of the cell cycle (O’Donnell KA et al. 2005). Genes in the E2F 
family, particularly E2F1, E2F2, and E2F3, activate multiple genes resulting in 
cell cycle progression from G1 to S phase. Conversely, both E2F1 and E2F3 
can activate the miR-17-92 cluster, establishing a regulatory loop. Critical also 
to the antiapoptotic effects of this cluster is the down-modulation of two 
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validated targets: the antiapoptotic protein Bim and the tumor suppressors 
PTEN and p21 (Ventura et al. 2008, Petrocca et al. 2008). The current theory is 
that like miR-155, this cluster induces lymphoid proliferation that predisposes 
to secondary genetic abnormalities that will ultimately become a full-blown 
malignancy. Deletion of the miR-17-92 genomic locus has been described in 
16.5% of ovarian cancers, 21.9% of breast cancers, and 20% of melanomas 
(Mendell 2008, , Hossain et al. 2006). These observations raise the question 
whether there is a fine post-transcriptional mechanism that regulates the 
expression of individual miRNAs in this cluster. In addition, these data support 
a tumor suppressor role for miR-17-5p, which seems to contradict extensive 
data consistently showing upregulation of this cluster in cancer (Volinia et al. 
2006). This dual role, oncogene and tumor suppressor, has also been described 
in protein-coding genes involved in the pathogenesis of cancer, such as TP53 
(Lane and Benchimol 1990). It is possible that a miRNA can act either as an 
oncogene or as a tumor suppressor depending on the tissue and its 
transcriptome, including the miRNA targets expressed in that particular tissue.  
 
 
MicroRNA Expression in patients 
Confirmed 
targets 
Experimental data Function 
miR-15a 
miR-16-1 
downregulated in CLLa Bcl-2, Wt-1 
induce apoptosis and 
decrease  tumorigenicity 
TSa 
let-7 
(a,-b,-c,-d) 
downregulated in lung and breast 
cancer 
RAS, c-myc, 
HMGA2 
induce apoptosis TS 
miR-29 
(a,-b,-c) 
downregulated in CLL, AMLa 
(11q23), lung and breast cancers, 
and cholangiocarcinoma 
TCL-1, 
MCL1, 
DNMT3s 
induce apoptosis and 
decrease tumorigenicity 
TS  
miR-34  
(a-b-c)  
downregulated in pancreatic,colon 
and breast cancers 
CDK4, 
CDK6, 
cyclinE2, 
E2F3 
induce apoptosis TS  
miR-155  
upregulated in CLL, DLBCL,a FLT3-
ITDa AML, BL,a and lung and breast 
cancers 
c-maf 
induces 
lymphoproliferation, pre-
B lymphoma/leukemia in 
mice 
OGa 
miR-17-92 
cluster 
upregulated in lymphomas and in 
breast, lung, colon, stomach, and 
pancreas cancers 
E2F1, Bim, 
PTEN 
cooperates with c-myc to 
induce lymphoma in 
mice, transgenic miR-17-
92 
develop 
lymphoproliferative 
disorder 
OG 
miR-21  
upregulated in breast, 
colon,pancreas, lung, prostate, liver, 
and stomach cancer; AML(11q23); 
CLL; and glioblastoma 
PTEN, 
PDCD4, 
TPM1 
induces apoptosis and 
decreases tumorigenicity 
OG 
miR-72/ 
miR-373 
upregulated in testicular tumors LATS2 
promote tumorigenesis in 
cooperation with RAS 
OG 
 
Tabella 3 MiRNAs with experimental data supporting a tumor suppressor or oncogene function in cancer 
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1.2.4 miRNAs in tumor invasion and metastasis 
 
   Very few studies have addressed the role of miRNAs in tumor invasion and 
metastasis. For example it has been found that miR-10b was upregulated in 
metastatic breast cancer cells with respect to the primary tumors (Ma et al. 
2007). It has been reported that enforced expression of miR-10b in 
nonmetastatic breast tumor cells positively regulated cell migration and 
invasion and that the level of miR-10b expression in primary breast cancer 
tissues correlated with clinical progression. Using a different approach, Huang 
et al. analyzed a nonmetastatic breast cancer cell line migration after 
transduction with a miRNA expression library (Huang et al. 2008). The authors 
identified two miRNAs, miR-373 and miR-520c, that stimulated cancer cell 
migration and invasion in vitro and in vivo by blocking the adhesion molecule 
CD44. A significant upregulation of miR-373 and negative correlation with 
CD44 expression was found in breast cancer patients with metastasis. 
 
 
1.2.5 miRNA profiling to improve cancer diagnosis and therapy 
 
   It has been shown that miRNAs can differentiate between tissue types with 
high accuracy (Lu et al. 2005). Therefore, MiRNA profiling could represent an 
invaluable tool to classify tumors that represent diagnostic challenges. The 
discovery of distinctive miRNA signatures will likely improve the molecular 
classification of cancer. Several studies have shown that miRNA expression is 
predictive of outcome in solid tumors and hematological malignancies (Calin 
et al. 2005, Garzon et al. 2008, Takamizawa et al. 2004, Schetter et al. 2008). 
However, further studies will be needed to test whether miRNAs could be used 
to better stratify patients for treatment. Because aberrant miRNA expression is 
now recognized as a common feature of cancers, specific miRNAs are being 
considered as potential new biomarkers for cancer diagnosis and prognosis (Yu 
et al. 2008). 
On the other hand, since loss of function or gain of function of miRNAs 
contributes to the cancer initiation and progression, correction of these 
miRNAs and their regulated gene network could change the behavior of cancer 
cells, thereby making them a promising target for new drug development. 
There are several reasons to pursue a miRNA based therapeutic approach. 
First, a single miRNA can have many targets that are involved in different 
oncogenic pathways. For example, miR-29b targets MCL-1 (apoptosis) and 
DNMT3A and -3B (methylation); miR-181 targets BCL-2 (apoptosis), TCL-1 
(AKT pathway), and CD69 (adhesion); and miR-17-92 targets the E2F family 
(cell cycle), Bim (apoptosis), and angiogenesis. Therefore, modulating the 
level of a single miRNA could eventually affect many pathways at the same 
time. Second, since a small group of miRNAs, including miR-155, let-7a, miR-
21, and the miR- 17-92 cluster, are consistently deregulated in a wide variety of 
hematological malignancies and solid tumors, developing strategies to silence 
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or re-express these miRNAs will likely affect several groups of patients. Third, 
as a proof of principle, preliminary data indicate that using cholesterol-
modified antisense oligonucleotides to the mature miRNAs (named 
antagomirs
2
) is an effective approach to silence miRNA expression in mice 
(Krutzfeldt et al. 2005). This could be a valuable approach to silence miRNAs 
upregulated in cancer, such as miR-155 or miR-21. However, the use of 
cholesterol-based oligonucleotides could be too toxic for humans. Further 
research is needed to determine the best formulation. In addition, precise 
delivery to the cancer cell is needed to avoid unwanted miRNA effects that 
could result from targeting important genes in other healthy tissues. Promising 
miRNA formulations should be further evaluated by detailed pharmacokinetics 
and pharmacodynamics studies in animal models.  
Experimental evidence demonstrates that the modulation of specific miRNA 
alterations in cancer cells using miRNA replacement
3
 or anti-miRNA 
technologies can restore miRNA activities and repair the gene regulatory 
network and signaling pathways, in turn, reverse the phenotype of cancerous 
cells (Wu 2011). Numerous animal studies for miRNA-based therapy offer the 
hope of targeting miRNAs as alternative cancer treatment. Developing the 
small molecules to interfere with miRNAs could be of great pharmaceutical 
interest in the future. This approach has been used, for example, to increase 
Let-7 expression, which is significantly reduced in lung cancer cell lines and 
lung cancer tissues (Takamizawa et al. 2004).  
Interestingly, specific miRNA is capable of reprogramming the cancer cells 
into a pluripotent embryonic stem cell-like state (mirPS), which could be 
induced into tissue-specific mature cell types (Wu 2011). 
                                                     
2Antagomir is a member of a novel class of chemically engineered oligonucleotides, which are efficient 
and specific silencers of endogenous miRNAs. They are synthesized from a hydroxyprolinol linked 
cholesterol solid support and 2’-OMe phosphoramidites. 
 
3miRNA replacement therapy is a  strategy that consist of  adding the miRNAs missing, (for example  
miRNA-mimic oligos or vector-based miRNA expression) in the cancer cells to restore their “normal” 
functions. 
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2. AIM OF THE STUDY 
 
   Thyroid carcinomas are one of the most common malignancies of the 
endocrine system. Well-differentiated thyroid carcinomas include papillary 
(PTC) and follicular (FTC) carcinomas and the latter is usually a more 
aggressive form of cancer than the more common papillary type. Unlike PTC, 
it can be difficult to diagnose FTC without performing surgery because there 
are no characteristic changes in the way the thyroid cells look. Therefore, the 
only way to tell if a follicular neoplasm is a cancer, is to look at the entire 
capsule around the nodule and see if there is any sign of invasion. This 
difficulty in diagnosis is one of the most frustrating areas for physicians who 
study thyroid disease, because its surgery is often the only way of definitively 
diagnosing a thyroid nodule. The follicular variant of papillary thyroid 
carcinoma (FVPTC) is believed to behave in a clinical manner similar to 
classical papillary cancer and to follow a similar indolent course.  
The setting up of  molecular assays to analyze clinical tissues in the diagnosis 
and management of thyroid cancer would allow far more accurate 
characterization of individual tumors and maybe the early diagnosis of 
recurrence. 
MicroRNAs  have emerged as an important class of short endogenous RNAs 
that act as post-transcriptional regulators of genes. The analysis of microRNA 
expression profile in several types of cancer has shown an altered microRNA 
expression in cancer compared to the respective normal tissues, and several 
studies have delineated their role in predicting cancer progression and 
prognosis. Our lab has lately been looking for  aberrant miRNA expression 
profile that distinguishes unequivocally among PTCs, ATCs and normal 
thyroid tissue (Pallante et al. 2006, Visone et al. 2007, Pallante et al. 2010). 
Recent results show that miR-191 expression is up-regulated in breast, colon 
and lung cancers, (Volinia et al. 2006, Xi et al. 2006), whereas it appears 
downregulated in ovarian cancer (Wynendaele et al. 2010), severe 
medulloblastoma (Ferretti et al. 2008), in AML with normal karyotype (Garzon 
e al. 2008) and in melanomas where the low miR-191 expression correlates 
with a poor prognosis (Caramuta et al., 2010).  However, no targets for miR-
191 have been so far identified.  
Since miR-191 is deregulated  in several tumors, the aim of our work has been 
to investigate the expression of this microRNA in thyroid cancer, in order to 
evaluate the potential use of mir-191 as an additional diagnostic marker. On the 
other hand, the aim has been  to  assess the role that miR-191 has in thyroid 
cancer cells proliferation and migration, in vitro. Moreover, we have tried to 
unravel the mechanism of action miR-191 by validating bioinformatically 
predicted targets. Finally, we have looked for an inverse correlation between 
miR-191 and its target expression  in thyroid cancers, in order to validate its 
pathogenetic role.  
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3. MATERIALS AND METHODS 
 
 
3.1 Thyroid tissue samples 
 
   Human neoplastic thyroid tissues and normal adjacent tissue or the 
controlateral normal thyroid lobe were obtained from surgical specimens and 
immediately frozen in liquid nitrogen. Thyroid tumors were collected at the 
Service d’Anatomo- Pathologie, Centre Hospitalier Lyon Sud, Pierre Benite, 
France. Tissue from patients with follicular adenoma (n = 25), follicular 
thyroid cancer (n = 24), papillary thyroid cancer (n = 15), anaplastic thyroid 
cancer (n = 8) and follicular variant of papillary thyroid cancer (n = 6) was 
studied. All thyroid tissue diagnoses were confirmed histologically. 
 
 
3.2 RNA extraction and quantitative reverse transcription (qRT-PCR) 
 
   Total RNA isolation from human tissues and cells was performed with Trizol 
(Invitrogen) according to manufacturer’s instructions. RNA was extracted from 
paraffin-embedded specimens after pulverizing the tumors by using dry-ice-
chilled stainless steel mortar and pestles. The integrity of the RNA was 
assessed by denaturing agarose gel electrophoresis. qRT-PCR analysis was 
performed on a panel of FTC samples of human thyroid origin and on cells by 
using miScript Reverse Transcription Kit (Qiagen, Hilden, Germany). One µg 
of total RNA was reverse-transcribed. After a 5-fold dilution, 2 µl of the cDNA 
were amplifyed by using miScript SYBR
â
 Green PCR Kit (Qiagen) following 
manufacturer’s instructions. Primers (miScript Primer Assays; Qiagen) were: 
Hs_miR-191_1 (amplifying human miR-191) and Hs_RNU6B_2 (amplifying 
U6, used as loading control). For CDK6 and PTEN mRNA detection, we 
reverse transcribed total RNA from cell lines by using QuantiTect
â
 Reverse 
Transcription Kit and the qRT-PCR was performed by using Power SYBR
â
 
Green PCR Master Mix (Applied Biosystems, Charleroi, Belgium) and the 
following primers: CDK6_for 417: 5'-CCGAGTAGTGCATCGCGATCTAA-
3' and CDK6_rev
 
823: 5'-CTTTGCCTAGTTCATCGATATC-3', PTEN_for 
1823: 5'-GGGGAAGTAAGGACCAGAGAC-3' and PTEN_rev 1917: 5'- 
TCCAGATGATTCTTTAACAGGTAGC -3'  and G6PD_for: 5'-
ACAGAGTGAGCCCTTCTTCAA-3' and G6PD_rev: 5'-
ATAGGAGTTGCGGGCAAAG-3'. G6PD was used as an internal standard for 
data calibration.
 
The 2
–DDCt
 formula was used for the calculation of differential
 
gene expression.  
 
 
3.3 Cell cultures and stable transfections 
 
   The human thyroid carcinoma WRO cells were grown in Dulbecco’s 
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modified Eagle’s medium (Gibco Laboratories) containing 10% fetal bovine 
serum (GibcoLaboratories), 1% glutamine (Gibco Laboratories), and 1% 
ampicillin/streptomycin (Gibco Laboratories) in a 5% CO2 atmosphere. 
For stable transfections, 5x10
5
 cells were plated in 100 mm plates and 1.8 mg 
of the pre-miR-191 expressing vector or the empty vector were co-transfected 
with 0.2 mg CMV-neomicin construct, using FuGENE
â
 HD Transfection 
Reagent (Roche Diagnostics GmgH, Mannheim, Germany), following 
manufacturer’s instructions. 
 
 
3.4 Plasmids  
  
  The Lentivector-based Micro-RNA Precursor construct expressing pre-miR-
191 (PreMiR-191) and the corresponding empty vector (pCDH-CMV-MCS-
EF1-copGFP) were purchased by System Biosciences (Mountain View, CA) 
and stably transfected in WRO cells.  
For the CDK6-3'UTR luciferase reporter construct, the 1133 bp 3'-UTR region 
of CDK6 gene, including 2 the putative binding sites for miR-191, was 
amplified from WRO cells DNA by using the following primers:  
FwCDK6: 5'-CCACCACTCCCAACTTGAC-3' and RevCDK6 5'-
ATGCAATCTAGACTAGCACCCAGTAAGACATCC-3'. The amplified 
fragment was cut with XbaI and cloned into pGL3-Control firefly luciferase 
reporter vector (Promega, Madison, Wisconsin, USA) at the XbaI site (pGL3-
CDK6-3'UTR). Deletions of 8 and 7 bp into each of the seed regions of the 
CDK6 3'UTR construct were introduced by site directed mutagenesis (Eurofins 
MWG/Operon, Ebersberg Deutschland), in order to generate the mutant 
constucts Mut1 and Mut2, respectively (Figure 12). A mutant construct, in 
which both sites were deleted (Mut1+2) was also generated. Renilla luciferase 
vector (pRL-CMV), for transient transfection efficiency, was from Promega.  
 
 
3.5 Proliferation and cell cycle analysis  
   
   Proliferation was assayed by using the Cell Titer (Promega) colorimetric 
assay, following manufacturer’s instructions. Briefly, 1X 103 cells were plated 
in each well of a 96-well. The following day, 20 ul of Cell Titer were added to 
the medium, and the 96-well has been incubated at 37°C for 1 hour and then 
read in a 96-well plate reader at 450 nm. The experiment was performed in 
triplicate and assayed for 10 days, every other day.  
For Flow cytometric analysis, WROpCDH and WROmiR-191 stable clones 
were serum starved and analyzed by flow cytometry after 48 h. Cells were 
harvested in PBS containing 2 mM EDTA, washed once with PBS, and fixed 
for 2 h in cold ethanol (70%). Fixed cells were washed once in PBS and treated 
with 25 µg/ml RNase A in PBS for 30 minutes, then washed again in PBS and 
stained with 50 µg/ml propidium iodide (Roche, Basel Switzerland) and 0,1% 
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Nonidet
Ò
P 40 Substitute (Sigma-Aldrich, St. Louis, MO). Stained cells were 
analyzed with a fluorescence activated cell sorter (FACS) Calibur (Becton-
Dickinson, Franklin Lakes, NJ, USA), and the data were analyzed using a 
mod-fit cell cycle analysis program. The measurements were performed in 
triplicate. 
 
 
3.6 Protein extraction, western blotting and antibodies 
 
Cells were scraped in ice-cold PBS, and then lysed in ice-cold NP40 lysis 
buffer (0.5% NP40, 50 mM HEPES (pH 7), 250 mM NaCl,5 mM EDTA, 50 
mM NaF, 0.5 mM Na3VO4, 0.5 mM phenylmethylsulfonyl fluoride, Complete 
inhibitor (Roche)). For Western blotting, 30 micrograms of protein from 
WROpCDH and WRO miR-191 were electrophoresed in 10% SDS–PAGE 
minigels and transferred onto Hybond C nitrocellulose membranes (GE 
Healthcare UK Ltd, Buckinghamshire, UK). The nitrocellulose membranes 
were incubated with primary antibodies anti-CDK6 (sc-177, Santa Cruz 
Biotechnology Inc., dilution 1: 1000), anti-PTEN (ab32199, Abcam, dilution 1: 
500), anti-actin (sc-1616, Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
dilution 1: 3000 ) or anti GAPDH (sc-32233, Santa Cruz, dilution 1: 5000) at 
4°C overnight, and then washed three times with Tris-Buffered Saline Tween-
20 (TBS 0,1% Tween). Afterwards, the nitrocellulose membranes were 
incubated with horseradish peroxydase (HRP)-conjugated donkey anti-rabbit 
(GE Healthcare UK Ltd, Buckinghamshire, England) (dilution 1: 3000) or 
donkey anti-goat IgG (Santa Cruz Biotechnology Inc.) (dilution 1:6000), 
respectively, for 1 hr at room temperature. After washing with TBST (TBS 
0,1% Tween), blots were visualized by using the Western blotting detection 
reagents (GE Healthcare UK Ltd). 
 
 
3.7 Dual-luciferase reporter assay 
 
   For dual-luciferase reporter assay, 3x105 WRO cells were  
co-transfected in 6-well plates with the pGL3-CDK6-3’UTR luciferase  
vector (400 ng) or with the mutated 3’UTR of CDK6 (Mut1, Mut2 and  
Mut1+2), together with the Renilla luciferase plasmid (4 ng) and the  
Pre-MiR-191 expressing constructs or the corresponding empty vector  
(1.6 µg), by using FuGENE HD Transfection Reagent (Roche Diagnostic  
Corporation, Indianapolis, IN). The pRL-TK control vector expressing  
Renilla luciferase (Promega) was used for normalization of cell number  
and transfection efficiency. Firefly and Renilla luciferase activity  
was measured 48h after transfection using the Dual-Luciferase Reporter  
Assay System (Promega) by a Lumat LB 9507 apparatus (Berthold  
Technologies, Bad Wildbad, Germany). 
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3.8 Cell migration assays? 
 
   A wound-induced migration assay (scratch assay) was performed as 
described previously (Angers-Loustau et al. 1999), with some modifications. 
Briefly, WROpCDH or WROmiR-191 cell clones were plated to form a 
monolayer, in presence of serum. The cells were then trypsinized, washed in 
PBS and allowed to attach on vitronectin-coated 6-well plates. Using a sterile 
yellow tip, a scratch was made in triplicate. Detached cells were removed, and 
the scratches were monitored for 24 hours under serum-free conditions. 
Migration rate was quantified by measuring the distance between the edges of 
wound and compared at t=0 to t=24h. In addition, a more quantitative 
haptotactic migration assay was performed essentially as described previously 
(Keely et al. 1995). Briefly, transwell inserts (8 µm pore size) in triplicates 
were coated on the underside with vitronectin (5 µg/ml). 2 x 104 cells were 
placed in the upper chamber in absence of serum (DMEM + 1%BSA) and 
allowed to migrate across inserts for 24 hours at 37°C. Unmigrated cells from 
the upper chamber were removed, and migrated cells in the lower side of the 
membrane were stained with crystal violet (0,5% in 25% methanol); after 
washing with PBS, cells were lysed in 1% SDS and the absorbance at 570 nm 
was measured. Each set of experiments was performed in triplicate. Statistical 
analysis of the data was performed using the paired Student's t-test.   
 
 
3.9 Immunohistochemistry 
 
   Five µm-thick paraffin sections were cleared in xylene and alcohol-
rehydrated. After microwave antigen retrieval with citrate
 
buffer, slides were 
treated with a 0,3% solution of hydrogen peroxidase in methanol to block the 
endogenous peroxidase activity for 30 min and then washed in phosphate 
buffer solution before immunoperoxidase staining. The slides were then 
incubated overnight at 4°C in a humidified chamber with the primary antibody 
(diluted 1:50 in PBS). Tissue sections were covered with biotinylated anti-
rabbit/anti-mouse immunoglobulins (Dako LSAB2 System) for 20 min, and 
then stained with streptavidin labeled with peroxidase; the signal was 
developed by using as substrate the diaminobenzidine (DAB-DAKO) solution 
containing 0.06 mM DAB and 2 mM hydrogen peroxide in 0.05% PBS pH 7.6 
for 5 min. After chromogen development, slides were washed, dehydrated with 
alcohol and xylene, and mounted with cover slips using a permanent mounting 
medium. Negative controls were performed by omitting the first antibody. 
The proportion of malignant cells positively stained was scored from 0 to 3: 0, 
no positive cells; 1+, ≤10% of positive cells; 2+, 11–50% of positive cells; and 
3+, >50% of positive cells. 
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4. RESULTS 
 
 
4.1 MicroRNA-191 expression is downregulated in thyroid follicular 
adenomas and carcinomas  
 
   In order to investigate the role of miR-191 in thyroid cancer, we analyzed 
mir-191 expression in 6 normal thyroid tissues and in a panel of thyroid 
neoplastic samples, including 25 follicular adenomas, 24 follicular carcinomas, 
15 PTCs, 8 ATCs and 6 follicular variant of PTCs (FVPTCs), by performing 
quantitative stem-loop RT-PCR.  
As shown in Figure 6, miR-191 is significantly downregulated in all the 
follicular adenomas (Figure 6A) and carcinomas (Figure 6B) compared to 
normal thyroid. However, the miR-191 expression levels are significantly 
lower in the carcinoma samples with respect to the adenomas. Conversely, in 
most PTCs, miR-191 expression is upregulated (Figure 6C) and it is 
upregulated just in 50% ATCs (Figure 6D) in comparison with normal thyroid 
tissues; interestingly, miR-191 expression in FVPTCs is downregulated (Figure 
6E), similarly to what observed for FTCs, even though at a lower extent. This 
result is suggestive of miR-191 downregulation as a signature for a follicular-
type behaviour (such as metastasis and blood invasion). 
 
 
 
Figure 6: miR-191 expression in thyroid 
tumors. Quantitative RT-PCR analysis of 
miR-191 expression in a panel of FAs (A), 
FTCs (B), PTCs (C), ATCs (D) and 
FVPTCs (E) of human thyroid origin. The 
fold change values indicate the relative 
change in the expression levels between 
tumor samples and the normal thyroid 
tissue, assuming that the value of the normal 
control sample was equal to 1. 
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4.2 miR-191 is downregulated in human thyroid carcinoma and 
retrovirally transformed rat thyroid cell lines  
 
   Subsequently, we analysed miR-191 expression in a panel of thyroid 
carcinoma cell lines of different histotypes, including WRO (from follicular 
carcinoma), FB2 and BCPAP (from papillary thyroid carcinoma), FRO and 
FB1 (from anaplastic carcinoma), compared to normal thyroid. As shown in 
Figure 7A, apart from the BCPAP cell line, a drastic reduction in miR-191 
expression with respect to normal thyroid tissue was observed in the thyroid 
carcinoma cell lines, independently from the histotype. 
In order to verify whether miR-191 is a more general event in thyroid 
neoplastic cell transformation, we analysed miR-191 expression in panel of rat 
thyroid cells deriving from the transformation of normal differentiated thyroid 
cells, PC Cl 3 and FRTL5 (Figure 7B), with the following viral oncogenes: v-
mos (PC 663), v-raf (PC raf), E1A plus v-raf (PC R15 raf), Ki-ras (PC kiki and 
FRTL5 Ki MSV), v-ras-Ha (PC Ha-ras) and Polyoma Middle T (PC Py), 
previously generated in our laboratory (Berlingieri et al., 1995). As shown in 
Figure 7B, all the transformed cell lines showed a drastic reduction in miR-191 
expression in comparison to the normal thyroid cells PC Cl3 and FRTL5, 
suggesting that miR-191 downregulation may be a general event in thyroid cell 
transformation.  
 
 
 
 
 
Figure 7: miR-191 expression in human and rat thyroid cell lines. Quantitative RT-PCR analysis of 
miR-191 expression in (A) human thyroid cell lines compared to normal thyroid and in (B) normal rat 
thyroid cell lines (PC Cl3 and FRTL5) and rat thyroid cell transformed by various oncogenes (PC 663, 
PC RAF, PC R15 RAF, PC KiKi, PC Ha, PC Py, FRTL5 Ki-MSV).  
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4.3 miR-191 expression affects cell shape, cell proliferation and migration 
of WRO cells 
 
   To define the role of miR-191 downregulation in the process of thyroid 
carcinogenesis we restored miR-191 expression levels in WRO cells by 
transfecting them with the PreMiR-191 Lentivector-based Micro-RNA 
Precursor construct, expressing preMiR-191, or with the corresponding empty 
vector (pCDH-CMV-MCS-EF1-copGFP), together with a plasmid confering 
neomycin-resistence. After selection, several GFP-positive clones were picked 
up, amplified and checked for miR-191 expression (Figure 8B), by quantitative 
RT-PCR. The selected WROmiR-191 cell clones (2 representative clones are 
showed in Figure 8A) showed an epithelial-like morphology, being more 
tightly packed, with respect to mock transfected WRO cells and to WRO cells 
transfected with the control vector (WRO-pCDH), which had a scattered 
distribution (Figure 8A). The acquisition of an epithelial phenotype is in 
agreement with a role of tumor suppressor, hypothesized for miR-191. 
 
 
 
 
 
 
 
 
Figure 8: WRO cells transfected with 
Lenti-miR-191 plasmid or with the 
empty vector. A: Phase contrast (a, c, e, 
g) and fluorescence (b, d, f, h) images of 
mock transfected WRO cells (a, b), WRO 
cells tansfected with the empty vector (c, 
d) and cells transfected with the miR-191 
expressing construct (representative 
clones) (e,f: WROmiR-191#1; g,h: WRO 
miR-191#3). B: Quantitative RT-PCR 
analysis of miR-191 expression in clones 
stably transfected with the pre-miR-191-
carrying vector or with the empty vector, 
compared to mock transfected cells. 
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In order to demostrate the tumor suppressive activity of miR-191, we assessed 
the proliferation rate in miR-191 and empty vector transfected WRO cells. The 
analysis of cell growth revealed a lower proliferation rate of the WRO-miR-
191 cell clones in comparison with the cells carrying the empy vector (Figure 
9A) or with mock transfected cells (Figure 9A).  
To better define the effect of miR-191 expression on cell cycle progression, we 
used flow cytometric analysis (FACS) to measure the DNA content of WRO 
miR-191 and WROpCDH cell clones. Transition from G1 to S phase was 
significantly lower in the WROmiR-191 cell clones than in the WROpCDH 
cells (Figure 9B). In fact, 19% of WROmiR-191 cells were in S phase and 52% 
in G0/G1 phase, whereas 24% of WROpCDH cells were in S phase and 45% in 
G0/G1 phase (Figure 9B).  
These results indicate that miR-191 overexpression decreases cell proliferation 
rate of a thyroid carcinoma cell line, retaining the cells in the G1 phase. 
 
 
 
 
 
Figure 9: miR-191 reduces proliferation and slows down the G1/S transition in WRO cells. A: The 
effect of miR-191 on WRO cells proliferation was assayed by Cell Titer. The diagram showes a reduction 
in proliferation in miR-191 transfected cells compared to cells transfected with the empty vector and to 
mock transfected cells. B: The effect of miR-191 on cell cycle was assayed by Flow cytometric analysis 
of WRO cells stably transfected with the miR-191 or the control vector. 
 
 
 
Since WROmiR-191 cells appeared less scattered on the cell culture plate, we 
evaluated cell motility in WROmiR-191 and control cells, by performing 
“scratch” and transwell chamber assays. As shown in Figure 10A, the migration 
(% wound closure) was comparable in WROmiR-191 and control cells, when 
assayed on plastic cell culture plates; conversely, when the scratch was 
performed on vitronectin treated plates, the motility of the WROmiR-191 cells 
was reduced (about 31%) compared with control cells (Figura 10A).  
Furthermore, we measured the invasive ability of the WRO-mir191 and WRO-
pCDH cells by performing a transwell migration assay and as shown in Figure 
10B, the ability of WRO cells to invade and cross the polycarbonate 
Nucleopore filters was reduced by the restoration of the miR-191 expression in 
WRO cells. This effetct was more evident on vitronectin (VN) coating (Figure 
10B). In this case the ability of WRO-mir191 cells to cross the membrane was 
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reduced by 30% compared to WROpCDH cells. This differential behaviour in 
presence or absence of VN suggest that at least one miR-191 target has to be 
implicated in the avb3–integrin-mediated inhibition. 
 
  
 
 
Figure 10: miR-191 expression reduces cell migration on Vitronectin. A: A wound-induced migration 
assay, in presence or absence of a vitronectin matrix coating, was performed using WROpCDH and 
WROmiR-191 cell clones in the absence of serum or growth factors. The extent of cell migration into the 
wounded area was photographed under phase-contrast microscopy at 0 hour and after 24 hours. 
Magnification, x100. Data shown are representative of three separate experiments and are diagrammed in 
the lower panel. Migration rate was quantified by measuring the distance between the edges of wound 
and compared at t=0 to t=24h. The migration rate is represented as percentages in graphics illustrating the 
reduction of wound closure in WROmiR-191 cell clones, plated on VN. B: Diagram of transwell assays, 
performed in presence (right panel) or absence (left panel) of VN coating. Migration is expressed as 
percent of adsorbance at 570 nm, compared to control cells. 
Empty Vitronectin 
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4.4 miR-191 downregulates CDK6 expression 
 
   MicroRNAs act on many cellular processes by modulating the expression of 
mRNA targets. Therefore, to investigate the mechanism by which miR-191 
may affect tumorigenesis, cell proliferation and migration, we used 
bioinformatic tools (mirGen, Target Scan, Pictar and miRanda), to search for 
potential mRNA targets. We identified several genes involved in DNA 
replication, cell cycle control and cell death regulation that were potentially 
targeted by miR-191. Among them, we selected the CDK6 gene, which 
encodes a catalytic subunit of the protein kinase complex that is important for 
cell cycle G1 phase progression and G1/S transition (Serrano et al. 1993). We 
selected this gene also because the activity or amount of CDK6 is elevated in 
some cancer cells and lymphomas (Costello et al. 1997, Timmermann et al. 
1997, Corcoran et al. 1999). Two sites matching the miR-191 seed sequences 
were predicted in the 3’UTR of the CDK6 gene (Figure 11A). To validate the 
influence of miR-191 on the CDK6 target, we evaluated the expression of 
CDK6 protein levels in WRO, WROpCDH and WROmiR-191 cell clones, by 
Western blot analysis (Figure 11B). The introduction of miR-191 significantly 
decreased by almost 50%) CDK6 protein level.  
Interestingly, there were no significant changes in CDK6
 
mRNA levels in cells 
transfected with the miR-191 or with the empty vector (Figure 11C). These 
results are consistent with post-transcriptional regulation of the CDK6 protein 
by miR-191 and exclude its role in CDK6 mRNA degradation. 
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Figure 11: MiR-191 expression downregulates CDK6 protein, but not mRNA expression. A: 
Alignment of miR-191 with the putative seed sequences in the CDK6 3’-UTR. B: Immunoblots for 
CDK6 in WRO, WROpCDH and WROmiR-191 cell clones. Immunoblot for α-actin has been used as 
loading control. C: qRT-PCR analysis of CDK6 mRNA in samples as in B. The fold change values 
indicate the relative change in CDK6 mRNA expression levels between control and miR-expressing cells, 
normalized with G6PD. 
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To determine whether direct interaction between miR-191 and CDK6 mRNA 
caused the decrease in CDK6 protein expression, we performed luciferase 
assays. To this aim, we inserted a sequence corresponding to the CDK6 3’UTR 
downstream of the luciferase gene, by cloning into the pGL3-control vector. 
This reporter vector was co-transfected into WRO cells, together with the miR-
191 expressing construct or the corresponding empty vector. Luciferase 
activity, measured 48 h later, resulted significantly reduced by miR-191 
expression, in a dose-dependent manner, as compared with cells transfected 
with the control vector (Figure 12B). These results indicate that miR-191 
interferes with CDK6 mRNA translation by directly interacting with the 
3’UTR. This conclusion is supported by similar experiments in which we used 
a reporter construct carrying target sites modified by 8 nucleotides-deletion in 
one or both sites. MiR-191 ability of downregulating luciferase activity was 
lost when either or both sites were mutated, suggesting that miR-191 acts 
through interaction with both sites (Figure 12B). 
These data show that miR-191 directly downregulate CDK6 protein 
expression, by interacting with two seed sequences in its 3’UTR. 
 
 
 
 
Figure 12: The 3’-UTR of 
CDK6 is a target of miR-
191. A: The two seed 
sequences for miR-191 in 
CDK6-3’UTR, with the 
respective mutants (Mut1 
and Mut2). Mut1+2 
contained both 
modifications. B: Relative 
luciferase activity in WRO 
cells transiently transfected 
with increasing amounts of 
Lenti-miR-191 or the empty 
vector (pCDH). The relative 
activity of firefly luciferase 
expression was standardized 
to a transfection control 
using Renilla luciferase. C: 
Relative luciferase activity 
in WRO cells transiently 
transfected with the Lenti-
miR-191, was assayed in 
presence of the wild-type 
CDK6 3’UTR sequence or 
with the mutants (Mut1, 
Mut2 and Mut1+2) and 
compared to the luciferase 
activity measured with the 
empty (pCDH) vector.  
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4.5 CDK6 overexpression inversely correlates with miR-191 in thyroid 
tumors 
 
   To understand if the CDK6 targeting by miR-191 has a pathological role in 
thyroid tumorigenesis, we evaluated the expression of the CDK6 protein in 20 
thyroid tissue specimens (5 normal thyroid tissues, 5 follicular adenomas, 5 
follicular carcinomas, and 5 papillary carcinomas) by immunohistochemical 
analysis. As shown in Figure 13, we found that CDK6 is not detectable in 
thyrocytes  from normal glands (Figure 13A) (5 out of 5) and is weakly 
expressed only in 1 out of 5 PTCs (Figure 13C), with few focally distributed 
cytoplasmic-positive tumour cells (20%). In contrast, we detected clear 
cytoplasmic and nuclear CDK6 stainings in 4 out of 5 follicular adenomas 
(Figure 13B), in more than 50% cells and in 3 out of 5 follicular carcinomas 
(Figure 13D). The immunohistochemical results are summarized in the table of 
Figure 13. Thus, CDK6 expression is inversely related to miR-191 levels in 
thyroid carcinomas and this inverse correlation has, at least in part, a 
pathogenic role in thyroid cancerogenesis. Interestingly, PTCs showed very 
faint CDK6 immuostainings, identifying the miR-191 downreguation/CDK6 
overexpression as peculiar to follicular thyroid cancers. 
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Figure 13: Immunohistochemical analysis for CDK6 in normal and malignant thyroid tissues. 
Representative anti-CDK6 immunostainings of a normal thyroid (A), a follicular thyroid adenoma (B), a 
thyroid papillary carcinoma (C) and thyroid follicular carcinoma (D). (Magnification: 200 x). 
E: Table summarizing the results of CDK6 immunohistochemistry on thyroid tumors. The proportion of 
malignant cells positively stained was scored from 0 to 3: 0, no positive cells; 1+, ≤10% of positive cells; 
2+, 11–50% of positive cells; and  3+, >50% of positive cells. 
 
Histotype 
Number 
of cases 
Number of samples with the indicated grade 
of positivity 
  0 1+ 2+ 3+ 
Normal Thyroid tissues 5 5 0 0 0 
Follicular Adenomas 5 0 0 1 4 
Papillary Carcinomas 5 0 4 1 0 
Follicular Carcinomas 5 0 0 2 3 
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5. Discussion 
 
   Mature functional miRNAs of approximately 22 nucleotides, that are 
generated from long primary miRNA (pri-miRNA) transcripts, control gene 
expression at the post-transcriptional level by degrading or repressing target 
mRNAs. Some miRNAs aberrantly expressed in cancer have been well 
documented (Chan et al., 2005; Pallante et al., 2006; Garzon et al., 2008). They 
were found to regulate the expression of signaling molecules, such as 
cytokines, growth factors, transcription factors, and proapoptotic and 
antiapoptotic genes. 
In our study we have investigated the role of miR-191 in thyroid neoplasias. 
We have reported that miR-191 was significantly downregulated in TA and 
FTC with a fold change higher in FTCs. Conversely, miR-191 was upregulated 
in PTCs, whereas it was up- or downregualted in ATCs, suggesting that miR-
191 downregulation is specific for the pathway leading to follicular neoplastic 
phenotype. Even though the opposite pattern of miR-191 expression in FTC 
and PTCs might appear contradictory, a similar situation has been already 
described by Aldred and colleagues (Aldred et al., 2004), which found that 
IGFBP6 is overexpressed in PTCs and downregulated in FTCs. Moreover, 
these Authors found that PTCs were characterized by the overexpression of 
CITED1 (Cbp/p300-interacting transactivator): a consensus sequence for p300 
and cEBP/beta is found in the miR-191 promoter region (Battista S., 
unpublished results) and might be responsible of miR-191 upregulatio in PTCs.  
Downregulation of miR-191 in TA (thyroid adenoma) with respect to normal 
thyroid indicated that miR-191 downregulation may be an early event in 
thyroid carcinogenesis. This hypothesis is consistent with data showing that 
miR-191 is found downregulated in lungs of rats exposed to environmental 
cigarette smoke (ECS) (Izzotti et al., 2009) and in pre-cancerous 
azoxymethane-(AOM)-induced colon lesions in rats (Davidson et al., 2009). 
This precocious downregulation of miR-191 may be suggestive not just of an 
early event, but also, on the other hand, of a protective, anti-cancer effect 
associated to its expression. Such a role is supported by data showing that the 
chemoprotective effect of nutritional bioactives (such as fish oil) is mediated 
by the up-regulation of miR-191 (and other miRNAs) (Davidson et al., 2009).  
The involvement of miR-191 downregulation in thyroid carcinogenesis seems 
validated by functional studies. Indeed, we show that miR-191 possesses anti-
proliferative potential and regulates cell cycle transition from G1 to S in 
thyroid follicular carcinoma derived cell lines; in these cells, miR-191 also 
induced morphological changes and reduced migration. In order to identify the 
mechanism by which miR-191 may affect part or all these processes, we 
looked for possible targets. We identified CDK6 mRNA as a miR-191 target. 
Indeed, miR-191 overexpression reduces the CDK6 protein levels and the 
luciferase activity of about 50%. Moreover, the deletion of few nucleotides in 
either or both the seed sequences in CDK6 3’-UTR leads to the inhibition of 
the miR-191 activity.  
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Consistently, in this study and in others, an increased CDK6 expression is 
observed in thyroid carcinomas (Kebebew et al., 2006). Here we show that 
CDK6 overexpression is tightly related to miR-191 downregulation in human 
thyroid tumors, being PTCs almost negative. These data confirm the functional 
role of miR-191 in thyroid cancerogenesis, suggesting that the inverse 
correlation between miR-191 and CDK6 expression may be indicative of a 
follicular phenotype. 
CDK6 has proto-oncogenic properties, and its activity is carefully regulated at 
multiple levels, as misregulation can induce unscheduled proliferation, and 
genomic and chromosomal instability. CDK4/CDK6, in complex with D-type 
cyclins (D1, D2, or D3), regulate the G1/S phase transition. Elevated activity 
of CDK6 may result in hyperphosphorylation of the retinoblastoma protein 
and, therefore, compromise its negative growth-regulatory activity (Harbour et 
al., 1999). Accordingly, restoration of miR-191 expression produces a cell 
phenotype similar to that induced by CDK6 inhibition, leading to retention in 
the G1 phase of the cell cycle and inhibition of cell migration on vitronectin 
(Alhaja et al., 2005). 
The potential use of micro-RNAs in cancer therapy would take advantage of 
theitr target multiplicity. Indeed, our in vitro preliminary results suggest that 
replacement therapy with miR-191 might affect, beside the cyclins circle, the 
PTEN/PI3K/AKT pathway, a pathway identified as an important target for 
drug discovery (Carnero et al., 2008). In fact, we observed that, whereas WRO 
cells express low levels of PTEN mRNA and protein, transfection with a miR-
191 expressing construct upregulates PTEN both at mRNA an protein level, 
compared to empty vector transfected cells. Loss of PTEN activity plays a role 
both in familiar (Cowden disease) and sporadic thyroid carcinomas (reviewed 
in Paes and Ringel 2008). Mechanisms for its inactivation include intragenic 
PTEN mutations, loss of heterozygosity (LOH) at the PTEN locus, promoter 
hypermethylation (mostly in follicular thyroid cancer), inappropriate 
subcellular compartimentalization.  
Since the PTEN-PI3K-AKT pathway appears to play a prominent role in 
advanced forms of the disease, and hence likely represents an important focus 
for development of targeted therapies, future experiments will aim at 
investigating the mechanism of miR-191-induced PTEN expression. Bio-
informatically predicted miR-191 targets include genes coding for transcription 
factors inhibiting PTEN trascription (such as pCAF and FOXO1), as well as 
protein kinases responsible of PTEN phosphorylation and degradation (Casein 
kinase 2 and GSK3). One or all of these targets, if validated, might mediate the 
mir-191 induced PTEN overexpression. 
The association between miR-191 and PTEN expression has also important 
implication concerning lung cancerogenesis. In fact, miR-191 is downregulated 
in rats treated with environmental cigarette smoke (ECS) (Izzotti et al. 2009). 
Smoke induces PTEN downregulation both in vivo and in vitro (Shaykhiev et 
al., 2010) and loss of PTEN expression is a poor prognostic factor for patients 
with NSCLC (Tang et al 2006).It will be interesting to investigate if PTEN is a 
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downstream indirect target of miR-191 downregulation in lung cancerogenesis 
and if a miR-191 replacement therapy might have protective effects. 
 
 
 
 
 
 
 
Figura 14: MiR-191 reintroduction induces PTEN overexpression. A: Immunoblots for PTEN in 
WROpCDH and WROmiR-191 cell clones. Immunoblot for GAPD has been used as loading control. B: 
qRT-PCR analysis of PTEN mRNA in samples as in A. The fold change values indicate the relative 
change in PTEN mRNA expression levels between control and miR-expressing cells, normalized with 
G6PD. 
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6. CONCLUSIONS 
 
   In conclusion the data reported here demonstrate that miR-191 is specifically 
downregulated in benign and malignant tumors of follicular histotype, with a 
fold-change that is significantly higher in follicular carcinomas with respect to 
adenomas. Conversely, in most PTCs and in 50% ATC miR-191 expression is 
upregulated, whereas, it is downregulated in FVPTCs, similarly to what 
observed for FTCs, suggesting that miR-191 downregulation may be a 
signature for a follicular-type behaviour and it could represent an ancillary 
diagnostic tool to discriminate the follicular neoplastic phenotype. 
Consistent with a putative tumour suppressor role of miR-191 in the 
development of thyroid neoplasias of the follicular histotype, we demonstrate 
that restoration of miR-191 expression in a follicular thyroid cancer cell line 
reduces cell growth, migration and cell proliferation rate, retaining the cells in 
the G1 phase of the cell cycle. 
Furthermore, we found that miR-191 negatively regulated the expression of 
CDK6, protein involved in cell cycle control, at the post-transcriptional level, 
without mRNA degradation. Therefore, CDK6 targeting might mediate the 
effect of miR-191 on cell-cycle. 
Finally, in follicular adenomas and carcinomas, we immunohistochemically 
detected CDK6 over-expression and demonstrated that it is inversely related to 
miR-191 levels in thyroid carcinomas, suggesting that miR-191 may contribute 
to thyroid cancerogenesis by controlling CDK6 expression. 
Moreover, our preliminary data suggest that the reintroduction of miR-191 
induces PTEN expression  
Even though the mechanism leading to PTEN upregulation needs to be further 
investigated, we can speculate that miR-191 might exert its anti-oncogenic 
effect also by targeting the PTEN/PI3K/AKT pathway. 
If this double control is confirmed, miR-191 might represent an additional 
molecule for cancer thyroid therapy 
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 Abstract 
 
miR-191 expression is frequently altered in several neoplasias, being upregulated in 
some cases, such as pancreatic, colon, lung and prostate carinomas, and 
downregulated in others, such as severe medulloblastomas and melanomas. In this 
study we have analysed  the expression of miR-191 in thyroid neoplasias. We report 
that miR-191 is downregulated in follicular adenomas and carcinomas, with a 
reduction that is almost 2-fold higher in follicular carcinomas with respect to 
adenomas, but upregulated in thyroid carcinomas of the papillary histotype (PTCs), in 
comparison with the normal thyroid tissue. Consistent with a putative tumour 
suppressor role of miR-191 in the development of thyroid neoplasias of the follicular 
histotype, functional studies showed that restoration of miR-191 expression in a 
follicular thyroid cancer cell line reduces cell growth and migration rate. 
Furthermore, we found that miR-191 negatively regulated the expression of CDK6 
protein, involved in cell cycle control, without changing the CDK6 mRNA level and 
decreased the activity of a luciferase reporter construct containing the CDK6-
3'untranslated region. These results demonstrate that miR-191 regulates CDK6 at the 
post-transcriptional level, resulting in inhibition of cell proliferation and migration of 
a follicular thyroid carcinoma cell line. Finally, in follicular adenomas and 
carcinomas, we immunohistochemically detected CDK6 over-expression, suggesting 
that miR-191 may contribute to thyroid cancerogenesis by controlling CDK6 
expression. 
 
 Introduction 
 
Thyroid tumors are of two types: benign or malignant. Benign tumors are principally 
represented by adenomas, while malignant tumors are, in most cases, carcinomas. 
Thyroid carcinomas are one of the most common malignancies of the endocrine 
system, and accounts for approximately 1% of all newly diagnosed cancer cases 
(Aldred et al., 2004), with an increasing incidence all over the world (reviewed in 
Wartofsky, 2010). Well-differentiated thyroid carcinomas include papillary (PTC) 
and follicular (FTC) carcinomas. FTC generally comprises about 10% of all 
diagnosed thyroid cancers and is usually a more aggressive form of cancer than the 
more common papillary type. It is likely that FTCs can develop from pre-existing 
benign follicular adenomas or directly by passing the stage of adenoma. Unlike 
papillary thyroid cancer, it can be difficult to diagnose FTC without performing 
surgery because there are no characteristic changes in the way the thyroid cells look. 
Therefore, the only way to tell if a follicular neoplasm is a cancer, is to look at the 
entire capsule around the nodule and see if there is any sign of invasion. This 
difficulty in diagnosis is one of the most frustrating areas for physicians who study 
thyroid disease, because its surgery is often the only way of definitively diagnosing a 
thyroid nodule (Lin and Chao, 2006). The follicular variant of papillary thyroid 
carcinoma (FVPTC) is believed to behave in a clinical manner similar to usual or 
classical papillary cancer and to follow a similar indolent course. However, these 
innocuous-appearing lesions, although sharing nuclear features of papillary cancer, 
may behave clinically in an unexpectedly malignant fashion, giving rise to bone 
metastases and vascular invasion (Baloch and LiVosli, 2000). 
The aim of the scientific community is to set up molecular assays to analyze clinical 
tissues in the diagnosis and management of thyroid cancer then allowing far more 
accurate characterization of individual tumors and maybe the early diagnosis of 
recurrence. 
MicroRNAs (miRNAs or miRs) have emerged as an important class of short 
endogenous RNAs that act as post-transcriptional regulators of gene (Bartel et al., 
2000). One miRNA is capable of regulating several distinct mRNAs and, altogether, 
the human miRNAs identified so far are believed to modulate more than one-third of 
the mRNA species encoded in the genome (Lewis et al. 2003; John et al. 2004; 
Kiriakidou et al. 2004). Moreover, each gene may be regulated by more than one 
miRNA. Therefore, the potential regulatory circuitry afforded by miRNAs is 
enormous. The analysis of microRNA expression profile in several types of cancer 
has shown an altered microRNA expression in cancer compared to the respective 
normal tissues, and several studies and/or meta-analyses have delineated their role in 
predicting cancer progression and prognosis. Previous work has demonstrated an 
aberrant miRNA expression profile that distinguishes unequivocally among PTCs, 
ATCs and normal thyroid tissue (Pallante et al., 2006; Visone et al., 2007; Pallante et 
al., 2010).  
Recent results show that miR-191 expression is up-regulated in breast, colon and lung 
cancers, (Volinia et al., 2006; Xi et al., 2006), as well as in leukemic cell lines, 
including HL60 (Kasashima et al., 2004) and those expressing ALL1 fusion proteins 
(Nakamura et al., 2007), whereas it appears downregulated in severe 
medulloblastoma (Ferretti et al., 2008), in AML with normal karyotype (Garzon e al., 
2008) and in melanomas where the low miR-191 expression correlates with a poor 
prognosis (Caramuta et al., 2010). Genetic variants of miR-191 have been also 
recently described in patients with familial breast (Shen et al 2009) and ovarian (Shen 
et al., 2010) cancer. However, no targets for miR-191 have been so far identified.  
The aim of our work has been to investigate the role of miR-191 in thyroid 
carcinogenesis. First, we report that miR-191 is downregulated in follicular adenomas 
and carcinomas, but not in PTCs, in comparison with the normal thyroid tissue, with 
a fold-change that is significantly higher in FTC with respect to TA. Restoration of 
miR-191 expression in thyroid carcinoma cell lines reduces cell proliferation leading 
to an increased number of cells in the G1 phase of the cell cycle. The identification of 
the CDK6 gene, coding for a protein involved in cell cycle control,  as target for miR-
191, accounts for the effects of miR-191 on the cell cycle, and, then, for the role of 
miR-191 in thyroid cancerogenesis. Immunohistochemisty showing the 
overexpression of CDK6 proteins in follicular-type tumors validate this hypothesis. 
 
 
 Materials and methods 
 
Thyroid tissue samples 
!"#$%& %'()*$+,-.& ,/01(-2& ,-++"'+& $%2& %(1#$*& $23$.'%,& ,-++"'& (1& ,/'&
.(%,1(*$,'1$*& %(1#$*& ,/01(-2& *(4'&5'1'& (4,$-%'2& 61(#& +"17-.$*& +)'.-#'%+& $%2&
-##'2-$,'*0& 61(8'%& -%& *-9"-2& %-,1(7'%:& ;/01(-2& ,"#(1+& 5'1'& .(**'.,'2& $,& ,/'&
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RNA extraction and quantitative reverse transcription (qRT-PCR) 
Total RNA isolation from human tissues and cells was performed with Trizol 
(Invitrogen) according to manufacturer’s instructions. RNA was extracted from 
paraffin-embedded specimens after pulverizing the tumors by using dry-ice-chilled 
stainless steel mortar and pestles. The integrity of the RNA was assessed by 
denaturing agarose gel electrophoresis. qRT-PCR analysis was performed on a panel 
of FTC samples of human thyroid origin and on cells by using miScript Reverse 
Transcription Kit (Qiagen, Hilden, Germany). One !g of total RNA was reverse-
transcribed. After a 5-fold dilution, 2 !l of the cDNA were amplifyed by using 
miScript SYBR! Green PCR Kit (Qiagen) following manufacturer’s instructions. 
Primers (miScript Primer Assays; Qiagen) were: Hs_miR-191_1 (amplifying human 
miR-191) and Hs_RNU6B_2 (amplifying U6, used as loading control). For CDK6 
mRNA detection, we reverse transcribed total RNA from cell lines by using 
QuantiTect ! Reverse Transcription Kit and then qRT-PCR for CDK6 was 
performed by using Power SYBR! Green PCR Master Mix (Applied Biosystems, 
Charleroi, Belgium) and the following primers: CDK6_for 417: 5'-
CCGAGTAGTGCATCGCGATCTAA and CDK6_rev
 
823: 5'-
CTTTGCCTAGTTCATCGATATC and G6PD_for: 5’-
ACAGAGTGAGCCCTTCTTCAA and G6PD_rev: 5’-
ATAGGAGTTGCGGGCAAAG. G6PD was used as an internal standard for data 
calibration.
 
The 2
–
""
Ct
 formula was used for the calculation of differential
 
gene 
expression. 
 
Cell cultures and stable transfections 
The human thyroid carcinoma WRO cells were grown in Dulbecco’s modified 
Eagle’s medium (Gibco Laboratories) containing 10% fetal bovine serum 
(GibcoLaboratories),1% glutamine (Gibco Laboratories), and 1% 
ampicillin/streptomycin (Gibco Laboratories) in a 5% CO2 atmosphere. 
For stable transfections, 5x10
5
 cells were plated in 100 mm plates and 1.8 µg of the 
pre-miR-191 expressing vector or the empty vector were co-transfected with 0.2 µg 
CMV-neomicin construct, using FuGENE! HD Transfection Reagent (Roche 
Diagnostics GmgH, Mannheim, Germany), following manufacturer’s instructions. 
 
Plasmids  
The Lentivector-based Micro-RNA Precursor construct expressing pre-miR-191 
(PreMiR-191) and the corresponding empty vector (pCDH-CMV-MCS-EF1-
copGFP) were purchased by System Biosciences (Mountain View, CA) and stably 
transfected in WRO cells.  
For the CDK6-3’UTR luciferase reporter construct, the 1133 bp 3’-UTR region of 
CDK6 gene, including 2 the putative binding sites for miR-191, was amplified from 
WRO cells DNA by using the following primers:  
FwCDK6: 5’-CCACCACTCCCAACTTGAC and RevCDK6 5’-
ATGCAATCTAGACTAGCACCCAGTAAGACATCC. The amplified fragment was 
cut with XbaI and cloned into pGL3-Control firefly luciferase reporter vector 
(Promega, Madison, Wisconsin, USA) at the XbaI site (pGL3-CDK6-3’UTR). 
Deletions of 8 and 7 bp into each of the seed regions of the CDK6 3’-UTR construct 
were introduced by site directed mutagenesis (Eurofins MWG/Operon, Ebersberg 
 Deutschland), in order to generate the mutant constucts Mut1 and Mut2, respectively 
(Fig. 4B). A mutant construct, in which both sites were deleted (Mut1+2) was also 
generated. Renilla luciferase vector (pRL-CMV), for transient transfection efficiency, 
was from Promega.  
 
Proliferation and colony assay  
Proliferation was assayed by using the Cell Titer (Promega) colorimetric assay, 
following manufacturer’s instructions. Briefly, 1X 103 cells were plated in each well 
of a 96-well. The following day, 20 ul of Cell Titer were added to the medium, and 
the 96-well has been incubated at 37°C for 1 hour and then read ina 96-well plate 
reader at 450nm. The experiment has been performed in triplicate and assayed for 10 
days, every other day. 
Colony assay was performed as previously described (Pallante et al., 2008). 
 
Flow cytometric analysis 
WROpCDH and WRO miR-191 stable clones were serum starved and analyzed by 
flow cytometry after 48 h. Cells were harvested in PBS, washed once with PBS, and 
fixed for 2 h in cold ethanol (70%). Fixed cells were washed once in PBS and treated 
with 25 !g/ml RNase A in PBS for 30 minutes, then washed again in PBS and 
stained with 50 !g/ml propidium iodide (Roche, Basel Switzerland) and 0,1% 
Nonidet#P 40 Substitute (Sigma-Aldrich, St. Louis, MO). Stained cells were analyzed 
with a fluorescence activated cell sorter (FACS) Calibur (Becton-Dickinson, Franklin 
Lakes, NJ, USA), and the data were analyzed using a mod-fit cell cycle analysis 
program. The measurements were performed in triplicate. 
 
Protein extraction, western blotting and antibodies 
Cells were scraped in ice-cold PBS, and then lysed in ice-cold NP40 lysis buffer 
(0.5% NP40, 50 mM HEPES (pH 7), 250 mM NaCl,5 mM EDTA, 50 mM NaF, 0.5 
mM Na3VO4, 0.5 mMphenylmethylsulfonyl fluoride, Complete inhibitor (Roche)). 
For Western blotting, 30 micrograms of protein from WROpCDH and WRO miR-
191 were electrophoresed in 10% SDS–PAGE minigels and transferred onto Hybond 
C nitrocellulose membranes (GE Healthcare UK Ltd, Buckinghamshire, UK). After 
incubating with primary antibodies anti-CDK6 (sc-177, Santa Cruz Biotechnology 
Inc.) and anti-actin (sc-1616, Santa Cruz Biotechnology Inc., Santa Cruz, CA) at 4°C 
overnight, the nitrocellulose membranes were washed three times with Tris-Buffered 
Saline Tween-20 (TBS 0,1% Tween) and then incubated with horseradish peroxydase 
(HRP)-conjugated donkey anti-rabbit (GE Healthcare UK Ltd, Buckinghamshire, 
England) (dilution 1: 3000) or donkey anti-goat IgG (Santa Cruz Biotechnology Inc.) 
(dilution 1:6000), respectively, for 1 hr at room temperature. After washing with 
TBST, blots were visualized by using the Western blotting detection reagents (GE 
Healthcare UK Ltd). 
 
Dual-luciferase reporter assay 
For dual-luciferase reporter assay, 3x10
5 
WRO cells were co-transfected in 6-well 
plates with the pGL3-CDK6-3’UTR luciferase vector (400 ng) or with the mutated 
3"-UTR of CDK6 (Mut1, Mut2 and Mut1+2), together with the Renilla luciferase 
plasmid (4 ng) and the Pre-MiR-191 expressing constructs or the corresponding 
empty vector (1.6 !g), by using FuGENE! HD Transfection Reagent (Roche 
Diagnostic Corporation, Indianapolis, IN). The pRL-TK control vector expressing 
Renilla luciferase (Promega) was used for normalization of cell number and 
transfection efficiency. Firefly and Renilla luciferase activity was measured 48h after 
transfection using the Dual-Luciferase Reporter Assay System (Promega) by a Lumat 
LB 9507 apparatus (Berthold Technologies, Bad Wildbad, Germany). 
 
Cell migration assays ! 
A wound-induced migration assay (scratch assay) was performed
 
as described 
previously (Angers-Loustau et al., 1999), with some modifications. Briefly,
 
WROpCDH or WROmiR-191 cell clones were plated to form a monolayer, in 
presence of serum.
 
 The cells were then trypsinized, washed in PBS and allowed to 
attach  on vitronectin-coated 6-well plates. Using a sterile yellow tip, a scratch was 
made in triplicate.
 
Detached cells were removed, and the scratches were monitored
 
for 
24 hours under serum-free conditions. Migration rate was quantified by measuring 
the distance between the edges of wound and compared at t=0 to t=24h. In addition,
 
a 
more quantitative haptotactic migration assay was performed
 
essentially as described 
previously (Keely et al., 1995). Briefly,
 
transwell inserts (8 !m pore size) in 
triplicates were
 
coated on the underside with vitronectin (5 !g/ml). 2 x 10
4
 cells were 
placed in the upper chamber in absence of serum (DMEM + 1%BSA) and allowed to 
migrate
 
across inserts for 24 hours at 37°C. Unmigrated cells from
 
the upper chamber 
were removed, and migrated cells in the lower
 
side of the membrane were stained 
with crystal violet (0,5% in 25% methanol); after washing with PBS, cells were lysed 
in 1% SDS and the absorbance at 570 nm was measured. Each set of experiments was 
performed in triplicate.
 
Statistical analysis of the data was performed using the paired
 
Student's t-test. 
 
Immunohistochemistry 
Five !m-thick paraffin sections were cleared in xylene and alcohol-rehydrated. After 
microwave antigen retrieval with citrate
 
buffer, slides were treated with a 0,3% 
solution of hydrogen peroxidase in methanol to block the endogenous peroxidase 
activity for 30 min and then washed in phosphate buffer solution before 
immunoperoxidase staining. The slides were then incubated overnight at 4°C in a 
humidified chamber with the primary antibody (diluted 1:50 in PBS). Tissue sections 
were covered with biotinylated anti-rabbit/anti-mouse immunoglobulins (Dako 
LSAB2 System) for 20 min, and then stained with streptavidin labeled with 
peroxidase; the signal was developed by using as substrate the diaminobenzidine 
(DAB-DAKO) solution containing 0.06 mM DAB and 2 mM hydrogen peroxide in 
0.05% PBS pH 7.6 for 5 min. After chromogen development, slides were washed, 
dehydrated with alcohol and xylene, and mounted with cover slips using a permanent 
mounting medium. Negative controls were performed by omitting the first antibody. 
The proportion of malignant cells positively stained was scored from 0 to 3: 0, no 
positive cells; 1+, #10% of positive cells; 2+, 11–50% of positive cells; and 3+, 
>50% of positive cells. 
 
 Results 
 
MicroRNA-191 expression is downregulated in thyroid follicular adenomas and 
carcinomas  
In order to investigate the role of miR-191 in thyroid cancer, we analyzed mir-191 
expression in 6 normal thyroid tissues and in a panel of thyroid neoplastic samples, 
including 25 follicular adenomas, 24 follicular carcinomas, 15 PTCs, 8 ATCs and 6 
follicular variant of PTCs (FVPTCs), by performing quantitative stem-loop RT-PCR.  
As shown in Figure 1, miR-191 is significantly downregulated in all the follicular 
adenomas (Figure 1A) and carcinomas (Figure 1B) compared to normal thyroid. 
However, the miR-191 expression levels were significantly lower in the carcinoma 
samples with respect to the adenomas. Conversely, in most PTCs, miR-191 
expression was upregulated (Fig. 1C) and it was upregulated just in 50% ATCs (Fig. 
1D) in comparison with normal thyroid tissues; interestingly, miR-191 expression in 
FVPTCs was downregulated (Figure 1E), similarly to what observed for FTCs, even 
though at a lower extent. This result is suggestive of miR-191 downregulation as a 
signature for a follicular-type behaviour (such as metastasis and blood invasion). 
 
 
MiR-191 is downregulated in human thyroid carcinoma and retrovirally 
transformed rat thyroid cell lines  
Subsequently, we analysed miR-191 expression in a panel of thyroid carcinoma cell 
lines of different histotypes, including WRO (from follicular carcinoma), FB2 and 
BCPAP (from papillary thyroid carcinoma), FRO and FB1 (from anaplastic 
carcinoma), compared to normal thyrioid. As shown in Figure 2A, apart from the 
BCPAP cell line, a drastic reduction in miR-191 expression with respect to normal 
thyroid tissue was observed in the thyroid carcinoma cell lines independently from 
the histotype. 
In order to verify whether miR-191 is a more general event in thyroid neoplastic cell 
transformation, we analysed miR-191 expression in panel of rat thyroid cells deriving 
from the transformation of normal differentiated thyroid cells, PC Cl 3 (Fig 2B) and 
FRTL5 (Figure  2C), with the following viral oncogenes: v-mos (PC 663), v-raf (PC 
raf), E1A plus v-raf (PC R15 raf), Ki-ras (PC kiki and FRTL5 Ki MSV), v-ras-Ha 
(PC Ha-ras) and Polyoma Middle T (PC Py), previously generated in our laboratory 
(Berlingieri et al., 1995). As shown in Figure 2B and 2C, all the transformed cell 
lines showed a drastic reduction in miR-191 expression in comparison to the normal 
thyroid cells PC Cl3 and FRTL5, suggesting that miR-191 downregulation may be a 
general event in thyroid cell transformation.  
 
miR-191 expression affects cell shape, cell proliferation and migration of WRO 
cells 
To define the role of miR-191 downregulation in the process of thyroid 
carcinogenesis we restored miR-191 expression levels in WRO cells by transfecting 
them with the PreMiR-191 Lentivector-based Micro-RNA Precursor construct, 
expressing preMiR-191, or with the corresponding empty vector (pCDH-CMV-MCS-
EF1-copGFP), together with a plasmid confering neomycin-resistence. After 
selection, several GFP-positive clones were picked up, amplified and checked for 
miR-191 expression (Fig. 3B), by quantitative RT-PCR. The selected WROmiR-191 
cell clones (2 representative clones are showed in Figure 3A) showed an epithelial-
like morphology, being more tightly packed, with respect to mock transfected WRO 
cells and to WRO cells transfected with the control vector (WRO-pCDH), which had 
a scattered distribution (Fig. 3A). The acquisition of an epithelial phenotype is in 
agreement with a role of tumor suppressor, hypothesized for miR-191. 
In order to demonstrate the tumor suppressive activity of miR-191, we assessed the 
proliferation rate in miR-191 and empty vector-transfected WRO cells. The analysis 
of cell growth revealed a lower proliferation rate of the WRO-miR-191 cell clones in 
comparison with the cells carrying the empy vector (Figure 4A) or with mock 
transfected cells (Fig. 4A). Moreover, we carried out a colony-forming assay 
performed on WRO cells after transfection with a vector carrying the miR-191 or the 
backbone vector. As shown in Figure 4B the WRO cells transfected with miR-191 
generated fewer colonies than cells transfected with the backbone vector. 
To better define the effect of miR-191 expression on cell cycle progression, we used 
flow cytometric analysis (FACS) to measure the DNA content of WRO miR-191 and 
WROpCDH cell clones. Transition from G1 to S phase was significantly lower in the 
WROmiR-191 cell clones than in the WROpCDH cells (Figure 4C). In fact, 19% of 
WROmiR-191 cells were in S phase and 52% in G0/G1 phase, whereas 24% of 
WROpCDH cells were in S phase and 45% in G0/G1 phase (Figure 4C).  
These results indicate that miR-191 overexpression decreases cell proliferation rate of 
a thyroid carcinoma cell line, retaining the cells in the G1 phase. 
Since WROmiR-191 cells appeared less scattered on the cell culture plate, we 
evaluated cell motility in WROmiR-191 and control cells, by performing “scratch” 
and transwell chamber assays. As shown in Figure 5A, the migration (% wound 
closure) was comparable in WROmiR-191 and control cells, when assayed on plastic 
cell culture plates; conversely, migration was reduced in WROmiR-191 cells 
compared to control, when the scratch was performed on vitronectin (VN)-treated 
plates, the motility of the WROmiR-191 cells was reduced (about 31%) compared 
with control cells (Figure 5A).  
Furthermore, we measured the invasive ability of the the WRO-mir191 and WRO-
pCDH cells by performing a transwell migration assays. As shown in Figure 5B, the 
ability of WRO cells to invade and cross the polycarbonate Nucleopore filters was 
slightly reduced by the restoration of the miR-191 expression in WRO cells. This 
effetc was more evident when the transwell underside was covered with VN (Fig 5B): 
in thic case, the ability of WRO-mir191 cells to cross the membrane was reduced by 
30% compared to WROpCDH cells. This differential behaviour in presence or 
absence of vitonectin suggest that at least one miR-191 target has to be implicated in 
the $v%3–integrin-mediated inhibition. 
 miR-191 downregulates CDK6 expression 
MicroRNAs act on many cellular processes by modulating the expression of mRNA 
targets. Therefore, to investigate the mechanism by which miR-191 may affect 
tumorigenesis, cell proliferation and migration, we used bioinformatic tools (mirGen, 
Target Scan, Pictar and miRanda), to search for potential mRNA targets. We 
identified several genes involved in DNA replication, cell cycle control and cell death 
regulation that were potentially targeted by miR-191. Among them we selected the 
CDK6 gene, which encodes a catalytic subunit of the protein kinase complex that is 
important for cell cycle G1 phase progression and G1/S transition (Serrano et al., 
1993). We selected this gene also because the activity or amount of Cdk6 is elevated in 
some cancer cells and lymphomas (Costello et al., 1997; Timmermann et al., 1997; 
Corcoran et al., 1999). Two sites matching the miR-191 seed sequences were 
predicted in the 3’UTR of the CDK6 gene (Figure 6A). To validate the influence of 
miR-191 on the CDK6 target, we evaluated the expression of CDK6 protein levels in 
WRO, WROpCDH and WROmiR-191 cell clones, by Western blot analysis (Figure 
6B). The introduction of miR-191 significantly decreased by almost 50%) CDK6 
protein level.  
Interestingly, there were no significant changes in CDK6 mRNA levels in cells 
transfected with the miR-191 or with the empty vector (Figure 6C). These results are 
consistent with post-transcriptional regulation of the CDK6 protein by miR-191 and 
exclude its role in CDK6 mRNA degradation. 
To determine whether direct interaction between miR-191 and CDK6 mRNA caused 
the decrease in CDK6 protein expression, we performed luciferase assays. To this 
aim, we inserted a sequence corresponding to the CDK6 3’UTR downstream of the 
luciferase gene, by cloning into the pGL3-control vector. This reporter vector was co-
transfected into WRO cells, together with the miR-191 expressing construct or the 
corresponding empty vector. Luciferase activity, measured 48 h later, resulted 
significantly reduced by miR-191 expression, in a dose-dependent manner, as 
compared with cells transfected with the control vector (Fig.7B). These results 
indicate that miR-191 interferes with CDK6 mRNA translation by directly interacting 
with the 3’UTR. This conclusion is supported by similar experiments in which we 
used a reporter construct carrying target sites modified by 8 nucleotides-deletion in 
one or both sites.  
MiR-191 ability of downregulating luciferase activity was lost when either or both 
sites were mutated, suggesting that miR-191 acts through interaction with both sites 
(Fig. 7B). 
These data show that miR-191 directly downregulate CDK6 protein 
expression, by interacting with two seed sequences in its 3’-UTR. 
 
CDK6 overexpression inversely correlates with miR-191 in thyroid tumors  
To understand if the CDK6 targeting by miR-191 has a pathological role in thyroid 
tumorigenesis, we evaluated the expression of the CDK6 protein in 20 thyroid tissue 
specimens (5 normal thyroid tissues, 5 follicular adenomas, 5 follicular carcinomas, 
and 5 papillary carcinomas) by immunohistochemical analysis. 
As shown in fig. 8, we found that CDK6 is not detectable
 
in thyrocytes from normal 
glands (Fig. 8A) (5 out of 5) and is weakly expressed only
 
in 1 out of 5 PTCs (Fig. 
8C), with few focally distributed cytoplasmic-positive
 
tumour cells (20%). In 
contrast, we detected clear cytoplasmic and nuclear CDK6 stainings in 4 out of 5 
follicular adenomas (Fig. 8B), in more than 50% cells and in 3 out of 5 follicular 
carcinomas (Fig. 8D). The immunohistochemical results are summarized in the table 
of Fig 8 E. 
Thus, CDK6 expression is inversely related to miR-191 levels in thyroid carcinomas 
and this inverse correlation has, at least in part, a pathogenic role in thyroid 
cancerogenesis. Interestingly, PTCs showed very faint CDK6 immuostainings, 
identifying the miR-191 downreguation/CDK6 overexpression as peculiar to 
follicular thyroid cancers.  
 Discussion 
Mature functional miRNAs of approximately 22 nucleotides that are generated from 
long primary miRNA (pri-miRNA) transcripts control gene expression at the post-
transcriptional level by degrading or repressing target mRNAs. Some miRNAs 
aberrantly expressed in cancer have been well documented (Chan et al., 2005; 
Pallante et al., 2006; Garzon et al., 2008). They were found to regulate the expression 
of signaling molecules, such as cytokines, growth factors, transcription factors, and 
proapoptotic and antiapoptotic genes. 
In this study we investigated the role of miR-191 in thyroid neoplasias. We report 
that miR-191 was significantly downregulated in TA and FTC with a fold change 
higher in FTCs. Conversely, miR-191 was upregulated in PTCs whereas it was up- or 
downregualted in ATCs, suggesting that miR-191 downregulation is specific for the 
pathway leading to follicular neoplastic phenotype. Even though the opposite pattern 
of miR-191 expression in FTC and PTCs might appear contradictory, a similar 
situation has been already described by Aldred and colleagues (Aldred et al., 2004), 
which found that IGFBP6 is overexpressed in PTCs and downregulated in FTCs. 
Moreover, these Authors found that PTCs were characterized by the overexpression 
of CITED1 (Cbp/p300-interacting transactivator): a consensus sequence for p300 and 
cEBP/beta is found in the miR-191 promoter region (Battista S., unpublished results) 
and might be responsible of miR-191 upregulatio in PTCs. 
Downregulation of miR-191 in AT with respect to normal thyroids indicated that 
miR-191 downregulation may be an early event in thyroid carcinogenesis. This 
hypothesis is consistent with data showing that miR-191 is found downregulated in 
lungs of rats exposed to environmental cigarette smoke (ECS) (Izzotti et al., 2009) 
and in pre-cancerous azoxymethane-(AOM)-induced colon lesions in rats (Davidson 
et al., 2009). This precocious downregulation of miR-191 may be suggestive not just 
of an early event, but also, on the other hand, of a protective, anti-cancer effect 
associated to its expression. Such a role is supported by data showing that the 
chemoprotective effect of nutritional bioactives (such as fish oil) is mediated by the 
up-regulation of miR-191 (and other miRNAs) (Davidson et al., 2009).  
The involvement of miR-191 downregulation in thyroid carcinogenesis seems 
validated by functional studies. Indeed, we show that miR-191 possesses anti-
proliferative potential and regulates cell cycle transition from G1 to S in thyroid 
follicular carcinoma derived cell lines; in these cells, miR-191 also induced 
morphological changes and reduced migration. In order to identify the mechanism by 
which miR-191 may affect part or all these processes, we looked for possible targets. 
We identified CDK6 mRNA as a miR-191 target. Indeed, miR-191 overexpression 
reduces the CDK6 protein levels and the luciferase activity of about 50%. Moreover, 
the deletion of few nucleotides in either or both the seed sequences in CDK6 3’-UTR 
leads to the inhibition of the miR-191 activity. Consistently, in this study and in 
others, an increased CDK6 expression is observed in thyroid carcinomas (Kebebew et 
al., 2006). Here we show that CDK6 overexpression is tightly related to miR-191 
downregulation in human thyroid tumors, being PTCs almost negative. These data 
confirm the functional role of miR-191 in thyroid cancerogenesis, suggesting that the 
inverse correlation between miR-191 and CDK6 expression may be indicative of a 
follicular phenotype. CDK6 has proto-oncogenic properties, and its activity is 
carefully regulated at multiple levels, as misregulation can induce unscheduled 
proliferation, and genomic and chromosomal instability. CDK4/CDK6, in complex 
with D-type cyclins (D1, D2, or D3), regulate the G1/S phase transition. Elevated 
activity of CDK6 may result in hyperphosphorylation of the retinoblastoma protein 
and, therefore, compromise its negative growth-regulatory activity (Harbour et al., 
1999). Accordingly, restoration of miR-191 expression produces a cell phenotype 
similar to that induced by CDK6 inhibition, leading to retention in the G1 phase of 
the cell cycle and inhibition of cell migration on vitronectin (Alhaja et al., 2005). 
Our preliminary data suggest that loss of miR-191 may predispose to thyroid cancer 
not just by CDK6 upregulation, but also by PTEN reduction. In fact, levels of Pten, 
the loss of which renders the thyroid highly susceptible to neoplastic transformation 
through mechanisms that include increased thyrocyte proliferation (Yeager et al., 
2007), are increased in miR-191 transfected WRO cells.  
Therefore, our data confirm a role of miR-191 in carcinogenesis. Indeed, its 
expression has been recently found altered in many kind of malignancies. Moreover, 
genetic variants of miR-191 (as well as of other six selected microRNA) have been 
described in patients with familial breast cancer (Shen et al., 2009). The C/G 
substitution affecting the pre-miRNA sequence, but not the mature miR-191 
sequence, is possibly translated into conformational changes in the predicted 
secondary structure, thereby blocking processing into the functional mature miRNA.  
In conclusion the data reported here demonstrate a that miR-191 is specifically 
downregulated in benign and malignant tumors of follicular histotype, and the 
targeting of the CDK6 gene might account for a role of miR-191 downregulation in 
thyroid carcinogenesis.  
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Figure 2: miR-191 expression in human and rat thyroid cell lines. Quantitative RT-PCR 
analysis of miR-191 expression in (A) human thyroid cell lines compared to normal thyroid and in 
(B) normal rat thyroid cell lines (PC Cl3 and FRTL5) and cells transformed by various oncogenes 
(PC 663, PC RAF, PC R15 RAF, PC kiki, PC Ha. PC Py and FRTL5 ki-MSV). 
 
Figure 3: WRO cells transfected with Lenti-miR-191 plasmid or with the empty 
vector. A: Phase contrast (a, c, e, g) and fluorescence (b, d, f, h) images of mock 
transfected WRO cells (a, b), WRO cells tansfected with the empty vector (c, d) and cells 
transfected with the miR-191 expressing construct (representative clones) (e,f: WROmiR-
191#1; g,h: WRO miR-191#3). B: M"$%,-,$,-='& N;@ACN& $%$*0+-+& (6&#-N@IOI& 'P)1'++-(% in 
clones stably transfected with the pre-miR-191-carrying vector or with the empty vector, 
compared to mock transfected cells.  
 
Figure 4: miR-191 reduces proliferation and slows down the G1/S transition in WRO 
cells. A: The effect of miR-191 on WRO cells proliferation was assayed by Cell Titer. The 
diagram showes a reduction in proliferation in miR-191 transfected cells compared to cells 
transfected with the empty vector and to mock transfected cells. B: The effect of miR-191 
on cell cycle was assayed by Flow cytometric analysis of WRO cells stably transfected 
with the miR-191 or the control vector. 
 
Figure 5: miR-191 expression reduces cell migration on Vitronectin. A: A wound-
induced migration assay, in presence or absence of a vitronectin matrix coating, was 
performed using WROpCDH and WROmiR-191 cell clones in the absence of serum or 
growth factors. The extent of cell migration into the wounded area was photographed 
under phase-contrast microscopy at 0 hour and after 24 hours. Magnification, x100. Data 
shown are representative of three separate experiments and are diagrammed in the lower 
panel. Migration rate was quantified by measuring the distance between the edges of 
wound and compared at t=0 to t=24h. The migration rate is represented as percentages in 
graphics illustrating the reduction of wound closure in WROmiR-191 cell clones, plated on 
VN. B: Diagram of transwell assays, performed in presence (right panel) or absence (left 
panel) of VN coating. Migration is expressed as percent of adsorbance at 570 nm, 
compared to control cells.  
 
Fig. 6: MiR-191 expression downregulates CDK6 protein, but not mRNA expression. 
A: Alignment of miR-191 with the putative seed sequences in the CDK6 3’-UTR. B: 
Immunoblots for CDK6 in WRO, WROpCDH and WROmiR-191 cell clones. Immunoblot 
for !-actin has been used as loading control. C: qRT-PCR analysis of CDK6 mRNA in 
samples as in B. The fold change values indicate the relative change in CDK6 mRNA 
expression levels between control and miR-expressing cells, normalized with G6PD. 
 
Figure 7: The 3’-UTR of CDK6 is a target of miR-191. A: The two seed sequences for 
miR-191 in CDK6-3’UTR, with the respective mutants (Mut1 and Mut2). Mut1+2 contained 
both modifications. B: Relative luciferase activity in WRO cells transiently transfected with 
increasing amounts of Lenti-miR-191 or the empty vector (pCDH). The relative activity of 
firefly luciferase expression was standardized to a transfection control using Renilla 
luciferase. C: Relative luciferase activity in WRO cells transiently transfected with the 
Lenti-miR-191, was assayed in presence of the wild-type CDK6 3’UTR sequence or with 
the mutants (Mut1, Mut2 and Mut1+2) and compared to the luciferase activity measured 
with the empty (pCDH) vector.  
 
Fig. 8: Immunohistochemical analysis for CDK6 in normal and malignant thyroid 
tissues.   
Representative anti-CDK6 immunostainings of a normal thyroid (A), a follicular thyroid 
adenoma (B), a thyroid papillary carcinoma (C) and thyroid follicular carcinoma (D). 
(Magnification: 200 x). 
E: Table summarizing the results of CDK6 immunohistochemistry on thyroid tumors. The 
proportion of malignant cells positively stained was scored from 0 to 3: 0, no positive cells; 
1+, "10% of positive cells; 2+, 11–50% of positive cells; and  3+, >50% of positive cells 
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